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Abstract
Cysteine-rich (C1) domains, present in PKC isozymes, Chimaerins, RasGRPs, PKDs, Munc13s, DGKs, and
MRCKs, can bind the diacylglycerol (DAG) second messenger. In the present thesis research, I
demonstrated that p23/Tmp21 acts as a C1-domain docking protein that mediates perinuclear
translocation of beta2-chimaerin. Glu227 and Leu248 in the beta2-chimaerin C1-domain are crucial for
binding p23/Tmp21 and perinuclear targeting. Isolated C1-domains from individual PKC isozymes or
RasGRP1 differentially interact with p23/Tmp21. PKCepsilon interacts with p23/Tmp21 specifically via its
C1b domain, however this association is lost in response to phorbol esters. These results demonstrate
that p23/Tmp21 acts as an anchor that distinctively modulates compartmentalization of C1-domaincontaining proteins, and it plays an essential role in beta2-chimaerin re-localization to the perinuclear
region in response to phorbol esters. It has been established that apoptosis induced by phorbol esters in
LNCaP cells is primarily mediated by the novel PKCdelta. I demonstrated that depletion of p23/Tmp21
significantly potentiates phorbol 12-myristate 13-acetate (PMA)-induced apoptosis in LNCaP cells.
Remarkably, the effect was mediated by PKCdelta as revealed by the fact that PKCdelta RNAi depletion or
PKC inhibitor GF 109203X can rescue the potentiating effect of p23/Tmp21 depletion.
Immunoprecipitation and confocal microscopy analysis demonstrated that PKCdelta and p23/Tmp21
formed a complex in LNCaP cells. Disruption of PKCdelta-p23/Tmp21 association by depletion of p23/
Tmp21 accelerates PMA-induced PKCdelta plasma membrane translocation and the activation of its
downstream effector ROCK and JNK. Moreover, I demonstrated that depletion of p23/Tmp21 potentiates
doxorubicin-mediated apoptosis of LNCaP cells. This work provided the first evidence that p23/Tmp21
negatively regulates PKCdelta-mediated apoptosis in LNCaP cells in response to PMA and doxorubicin. In
addition, I demonstrated that the PKC inhibitor GF 109203X significantly radiosensitizes PC3 androgenindependent prostate cancer cells. Depletion of PKCepsilon but not PKCalpha and PKCdelta by shRNA,
significantly radiosensitizes PC3 cells. Confocal images demonstrated that gamma-irradiation-induced
PKCepsilon membrane translocation was impaired by the EGFR inhibitor AG1478, the PLCgamma1
inhibitor U73122, or the ROS scavenger N-acetyl-cysteine (NAC). The results revealed a potential role for
DAG and C1-domain containing protein in the control of ionizing irradiation induced cell death/survival
and also suggested that inhibition of PKCepsilon may be a useful therapeutic approach to radiosensitize
prostate cancer cells. Taken together, in this work I present several novel findings that highlight the
relevance of C1-domain containing proteins in cancer.
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ABSTRACT
THE C1 DOMAIN IN CANCER SIGNALING MOLECULES: REGULATION
BY LIPIDS AND PROTEIN-PROTEIN INTERACTIONS
HONGBIN WANG
Marcelo G. Kazanietz. Ph.D.
Cysteine-rich (C1) domains, present in PKC isozymes, Chimaerins (a family of
small RacGTPase activating proteins), RasGRPs (a family of guanine nucleotide
exchange factor for Ras/Rap1), PKDs (the serine/threonine kinase protein kinase D),
Munc13s (the mammalian unc13), DGKs (the DAG kinases β and γ), and MRCKs
(the serine/threonine kinase myotonic dystrophy kinase-related Cdc42-binding
kinase), can bind the diacylglycerol (DAG) second messenger. In the present thesis
research, I demonstrated that p23/Tmp21 acts as a C1 domain docking protein that
mediates perinuclear translocation of β2-chimaerin. Glu227 and Leu248 in the β2chimaerin C1 domain are crucial for binding p23/Tmp21 and perinuclear targeting.
Isolated C1 domains from individual PKC isozymes or RasGRP1 differentially
interact with p23/Tmp21. PKCε interacts with p23/Tmp21 specifically via its C1b
domain, however this association is lost in response to phorbol esters. These results
demonstrate that p23/Tmp21 acts as an anchor that distinctively modulates
compartmentalization of C1 domain-containing proteins, and it plays an essential role
in β2-chimaerin re-localization to the perinuclear region in response to phorbol
esters. It has been established that apoptosis induced by phorbol esters in LNCaP
cells is primarily mediated by the novel PKCδ. I demonstrated that depletion of
iv

p23/Tmp21 significantly potentiates phorbol 12-myristate 13-acetate (PMA)-induced
apoptosis in LNCaP cells. Remarkably, the effect was mediated by PKCδ as revealed
by the fact that PKCδ RNAi depletion or PKC inhibitor GF 109203X can rescue the
potentiating effect of p23/Tmp21 depletion. Immunoprecipitation and confocal
microscopy analysis demonstrated that PKCδ and p23/Tmp21 formed a complex in
LNCaP cells. Disruption of PKCδ-p23/Tmp21 association by depletion of
p23/Tmp21 accelerates PMA-induced PKCδ plasma membrane translocation and the
activation of its downstream effector ROCK and JNK. Moreover, I demonstrated that
depletion of p23/Tmp21 potentiates doxorubicin-mediated apoptosis of LNCaP cells.
This work provided the first evidence that p23/Tmp21 negatively regulates PKCδmediated apoptosis in LNCaP cells in response to PMA and doxorubicin. In addition,
I demonstrated that the PKC inhibitor GF 109203X significantly radiosensitizes PC3
androgen-independent prostate cancer cells. Depletion of PKCε but not PKCα and
PKCδ by shRNA, significantly radiosensitizes PC3 cells. Confocal images
demonstrated that γ-irradiation-induced PKCε membrane translocation was impaired
by the EGFR inhibitor AG1478, the PLCγ1 inhibitor U73122, or the ROS scavenger
N-acetyl-cysteine (NAC). The results revealed a potential role for DAG and C1
domain-containing protein in the control of ionizing irradiation induced cell
death/survival and also suggested that inhibition of PKCε may be a useful therapeutic
approach to radiosensitize prostate cancer cells.
Taken together, in this work I present several novel findings that highlight the
relevance of C1 domain-containing proteins in cancer.
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CHAPTER 1

General Introduction
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The lipid second messenger diacylglycerol (DAG) and phorbol esters
1,2-diacyl-sn-glycerol (DAG) is a biologically active lipid second messenger that is
generated in response to various extracellular stimuli, including growth factors,
hormones, neurotransmitters, and a variety of other agonists. There are several
sources from which DAG can derive in cells, including: 1) phosphatidylinositol (4, 5)
bisphosphate (PtdIns (4, 5) P2) hydrolysis through the action of a phosphoinositidespecific phospholipase C (PI-PLC); 2) phosphatidylcholine (PC) hydrolysis by
phospholipase D (PLD), yielding phosphatidic acid (PA), which in turn is converted
to DAG by a specific PA phosphohydrolase; 3) PC hydrolysis by PC-PLC, or
phosphatidylcholine-ceramide cholinephosphotransferase, which produces DAG
(Figure 1.1). Among these routes, hydrolysis of phosphatidylinositol-4, 5biphosphate (PIP2) by specific PI-PLC enzymes into DAG and inositol-3,4,5triphosphate (IP3) has been extensively studied and considered as the major pathway
for the generation of DAG. Stimulation of G-protein coupled receptors (GPCRs) or
receptor tyrosine kinases (RTKs) activates phospholipase C (PLC) β and PLCγ
isozymes, respectively. While DAG remains in the plasma membrane and serves as a
ligand for classical and novel protein kinase C (PKC) isozymes as well as “nonkinase” DAG receptors (64, 151), the soluble IP3 activates Ca2+ channels to release
Ca2+ from the endoplasmic reticulum, which also can activate classical PKC together
with DAG.
Phorbol esters, natural compounds originally isolated from the plant croton
tiglium, mimic the effects of DAG on PKC (32). Phorbol esters have generated a lot
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of interest due to their tumor promoting properties in animal models of carcinogenesis
(162) and have been widely used as pharmacological tools to study DAG signaling

Figure 1. 1 Main pathways that lead to the production of DAG. OH is hydroxyl; R,
R’ are fatty acids; P is a phospho group; X is choline, ethanolamine, inositol or
serine; SM, sphingomyelin; SMS, sphingomyelin synthase; LPP, lipid phosphate
phosphatase; DGK, diacylglycerol kinase; PAP, phosphatidic acid phosphatase; PLC,
phospholipase C; PC-PLC, phosphatidicholine specific phospholipase C; PLD,
phospholipase D.
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pathway due to their high potency and stability (19, 84). The basic structure of
phorbols consists of four carbon rings, labeled A, B, C, and D. Substitutions in
positions 12 and 13 in ring C form a DAG-like structure. The most commonly used
phorbol ester is Phorbol 12-Myristate 13-Acetate (PMA), also called TPA
(Tetradecanoyl Phorbol Acetate) (Figure 1.2).

PKC isozymes: the first identified DAG/phorbol ester receptors
PKCs are a family of related serine/threonine kinases that regulate cellular
proliferation, differentiation, cell cycle, apoptosis, senescence, metastasis, malignant
transformation, and cancer progression (84). The enzymatic activity of PKC was first
identified in rat brain by Nishizuka and co-workers as a cytoplasmic serine- and
threonine-specific protein kinase (82, 171, 173). It was initially thought that this
protein kinase was proteolytically activated from a proenzyme. However, later on it
was found that the enzyme is reversibly activated in vitro by unsaturated DAG in the
presence of acidic phospholipids such as phosphatidylserine (172). This finding
provided the first evidence of a link between receptor-induced phosphatidylinositol
hydrolysis and activation of a protein kinase (91, 136). All PKC isoforms have a
highly conserved carboxyl terminal kinase domain and a more divergent aminoterminal regulatory domain linked by a hinge region. PKC in its inactive form is autoinhibited by a pseudosubstrate sequence present in the regulatory domain that
occupies the substrate-binding pocket in the otherwise functional kinase domain
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(144). PKC is activated when DAG and/or allosteric effectors bind to its regulatory
domain at the plasma membrane. This binding disrupts the docking of the regulatory

Figure 1.2 Structures of phorbol 12-myristate 13-acetate (PMA) and diacylglycerol (DAG).

5

domain, which displaces the bound pseudosubstrate region from the active site,
allowing for PKC kinase activation (132, 138). Based on their regulatory and
biochemical properties, PKC isozymes have been classified into 3 subgroups: the
“classical” or “conventional” PKCs (cPKCs) which comprise PKCα, βI, βII, and γ; the
“novel” PKCs (nPKCs), a group that includes PKCδ, PKCε, PKCη, and PKCθ; and
the “atypical” PKCs (aPKCs) which comprise PKCζ and PKCι/λ. Both cPKCs and
nPKCs are sensitive to DAG/phorbol esters, and only cPKCs are activated by
calcium. Atypical PKCs do not respond to either DAG/phorbol ester or calcium
(Figure 1.3).

PKCδ : a growth inhibitory and pro-apoptotic kinase
Phorbol esters cause growth inhibition or cell death in many cell types. PKCδ
seems to be responsible for many growth inhibitory effects, particularly through upregulation of p21cip1 (60). In many cell types, PKCδ has also been identified as a key
PKC isozyme involved in apoptosis triggered by a variety of stimuli, including
chemotherapy agents, H2O2, virus infection, phorbol esters, UV radiation, Fas-ligand,
and ionizing radiation (3, 15, 54, 58, 59, 93, 97, 149, 152, 158, 200, 204). Studies
from our laboratory and others demonstrated that in LNCaP prostate cancer cells the
phorbol esters activate PKCδ to trigger an apoptotic response (58). Subsequent
studies revealed that the JNK cascade acts as a mediator of phorbol ester-induced
LNCaP cell apoptosis. Additional analysis found that apoptosis is triggered by the
autocrine secretion of death factors, including TNFα and TRAIL, with subsequent
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Figure 1.3 The family of PKC isozymes.

7

activation of the extrinsic apoptotic cascade. A recent study by Xiao et al. in our
laboratory revealed that the Rho-ROCK-p21cip1 pathway is also implicated in phorbol
ester-induced prostate cancer cell apoptosis (193).
Numerous studies have demonstrated that PKCδ is activated by caspase-3
dependent proteolytic cleavage in response to stimuli. Caspase-3 can release a 40KDa constitutively active PKCδ catalytic fragment that subsequently phosphorylates
downstream substrates involved in the apoptotic process (54, 61). Phosphorylation of
tyrosine residues in PKCδ is also a critical step for its activation during apoptosis in
some models. For examples, tyrosines 64 and 187 become phosphorylated upon
exposure of etoposide, whereas residues of tyrosines 311, 332 and 512 become
phosphorylated in response to H2O2 in CHO cells (93).
Previous reports also suggested that PKCδ-triggered apoptosis depend on the
cellular context and stimulation, since PKCδ redistributes to different subcellular
compartments in response to apoptotic stimuli. Nuclear translocation of PKCδ can
mediate DNA-damage-induced apoptosis (49), in which PKCδ can act as an inhibitor
of activity of the catalytic subunit of DNA-PKs. DNA-PKs dissociate from DNA
after becoming phosphorylated by PKCδ, which subsequently interrupts the DNA
double strand break repair by nonhomologous end joining (14). In addition, in many
cell lines, PKCδ translocates to mitochondria upon treatment with phorbol esters or
by oxidative stress (20, 104, 113, 114). It is well established that translocation and
activation of PKCδ decrease mitochondrial membrane potential, resulting in the
release of cytochrome c, which is known to form a complex with Apaf-1 that
subsequently activates caspases and induces apoptosis (137).
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The involvement of PKCδ in apoptotic signaling is not universal. PKCδ activates
the ERK cascade and promotes proliferation in MCF-7 cells (88), enhances cell
survival and chemotherapeutic resistance in non-small lung cancer cells (40), and
increases breast tumor cell anchorage-independent growth (89), arguing that PKCδ
behaves differently in different cellular contexts.

PKCε: oncogenic and pro-survival effects
PKCε is believed to function as an anti-apoptotic protein and is the only PKC
isozyme shown to exhibit full oncogenic potential (8, 9, 24, 50, 62, 119, 124, 140,
161). When overexpressed in LNCaP androgen-dependent cancer cells, PKCε confers
androgen independence, accelerates G1/S transition, and enhances tumorigenic
potential in nude mice (191, 192). PKCε stimulates mitogenicity via the ERK
pathway. In addition, PKCε disrupts the reactivation of the tumor suppressor
retinoblastoma (pRb), derepresses transcriptional elongation of the c-myc oncogene,
and propagates survival signals in the absence of functional PTEN (190-192). PKCε
is highly expressed in many epithelial cancers (70). For example, PKCε is barely
detected by immunohistochemistry (IHC) in benign prostatic epithelium but is
overexpressed in > 95% of prostate tumors (44). A more recent analysis found that
high-grade human prostate tumors express very high PKCε levels (5). PKCε
expression is markedly up-regulated in prostate tumors from TRAMP (transgenic
adenocarcinoma mouse prostate) mice and correlates with high phospho-Akt levels
(5). A positive correlation has been also found between PKCε and Stat3 expression in
prostate cancer cells (5). Notably, de-regulation of the PKCε gene (PRKCE) has been
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reported in other cancer types, such as in lung, breast and thyroid cancer (6, 92, 142).
More recently, studies in breast cancer cells have linked PKCε to Akt to protect cells
against ionizing radiation induced cell death (108). Studies from our laboratory found
that PKCε could activate survival signaling both through Akt-dependent and Aktindependent mechanisms in prostate cancer cells (Meshki, J et al., submitted for
publication).
It was reported that PKCε prevents both DNA damage- and receptor-mediated
apoptosis. Anti-cancer drug resistance caused by overexpression of PKCε has been
demonstrated in many cancer types, such as ovarian, prostate, and non-small cell lung
cancer as well as in embryo fibroblast cells (8, 11, 50, 56). Studies also reported that
PKCε plays a protective role in TNFα- and TRAIL-mediated cancer cell death,
including in breast, glioma, and melanoma cells (9, 62, 157, 161). Several studies
have established that in different cells, PKCε can directly interact with Akt (108, 146,
179, 192). Akt is a downstream effector of phosphoinositol 3-kinase (PI3K) and plays
an essential role in cell survival and tumorigenesis through phosphorylation of a
number of downstream substrates (188). There is considerable evidence
demonstrating that PKCε is required for Akt phosphorylation in response to different
stimuli, such as insulin, hydrogen peroxide, heat shock, and ischemia-reperfusion
injury (107, 118, 146, 192, 203). PKCε also enhances Akt protein stability. A number
of studies also indicate that PKCε pro-survival function might be linked to Bcl-2
family proteins (10). Very recently, Basu and her colleagues demonstrated that
overexpression of PKCε in MCF-7 cells elevates Bcl-2 mRNA levels and reciprocally
decreases Bid expression (161), resulting in MCF-7 cell resistance to TRAIL. In line

10

with this report, a PKCε inhibitory peptide could effectively inhibit Bcl-2
phosphorylation and enhance H2O2-induced apoptosis in rat cardiomyocytes (115).
Overexpression of PKCε renders LNCaP prostate cancer cells resistant to apoptosis,
and PKCε-deficiency sensitizes these cells to PMA-induced apoptosis by preventing
Bax activation and translocation to mitochondria (121). However, a few reports
suggested that PKCε negatively regulates Akt functions (7, 71, 105, 107). Taken
together, the pro-survival function of PKCε appears to be dependent on the cellular
context and stimuli (105, 107, 186).

Ionizing irradiation and PKC isozymes
Although it has been conceived that upon ionizing radiation DNA damage/repair
and cell cycle checkpoint pathways are the key mechanisms that regulate cell
death/survival, accumulating evidence suggests that membrane-related signaling
cascades also play critical roles in controlling cell death/survival. It has been reported
that irradiation leads to PKC activation, suggesting that PKC might be a determinant
factor in radiosensitivity (73, 76, 77, 90, 129, 164). An early report by Nakajima et al.
revealed that γ-irradiation induces DAG production and activates PKC in cultured rat
hepatocytes. Using radical scavengers and a phospholipase C inhibitor, they conclude
that DAG generation and PKC activation are mediated through membrane lipid
peroxidation and PLC activation (129, 130). Interestingly, irradiation induced the
activation of EGFR and ERK signaling, which confers the cytoprotective effects (2).
Ionizing radiation can mimic the effect of EGF and activate EGFR. Sturla et al.
established that phosphorylation of Tyr992 in EGFR in response to ionizing
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irradiation is higher than that seen with EGF, suggesting that Tyr992 is an important
effector upon radiation-induced activation of EGFR (168). Phosphorylation of Tyr992
residue in EGFR promotes its coupling to PLCγ, leading to DAG generation and
[Ca2+] release which are implicated in PKC activation.

Novel DAG/phorbol ester receptors
The prevalent view that PKC isozymes are the only DAG/phorbol ester receptors
has been challenged after the discovery of additional DAG/phorbol ester receptors,
suggesting a high degree of complexity in the signaling pathways activated by
DAG/phorbol esters. At least six additional families of DAG/phorbol esters receptors
have been discovered to-date (Figure 1.4), including chimaerins (a family of small
RacGTPase activating proteins), RasGRPs (a family of guanine nucleotide exchange
factor for Ras/Rap1), the serine/threonine kinase myotonic dystrophy kinase-related
Cdc42-binding kinase (MRCK) family, the serine/threonine kinase protein kinase D
(PKD) family, the DAG kinases (DGK) β and γ, and the mammalian unc13 (Munc13)
proteins (involved in neurotransmitter secretion) (21, 86). Like classical and novel
PKC isozymes, all of these DAG/phorbol ester receptors possess a cysteine-rich
domain (C1 domain) that binds phorbol ester/DAG with high affinity. Moreover, the
novel DAG/phorbol ester receptors are also subject to subcellular redistribution upon
binding of phorbol esters or DAG, which facilitates their association with their
corresponding effectors.

The C1 domain: a DAG/phorbol ester binding motif

12

Figure 1.4 Novel DAG/phorbol esters receptors.

13

C1 domains are 50-51 amino acid long cysteine-rich motifs originally identified
in PKC as the binding sites for DAG and the phorbol esters. These domains contain
the characteristic motif: HX12CX2CX13/14CX2CX4HX2CX7C, where H is His, C is
Cys, and X is any other amino acid. X-ray crystallography analysis revealed that C1
domains are compact globular structures coordinated through binding of two Zn2+
ions to conserved Cys and His residues (Figure 1.5). While this motif is duplicated in
tandem (C1a and C1b domains) in cPKCs and nPKCs, a single copy is present in
aPKCs. Structural and ligand-binding analyses demonstrated that C1 domains in
cPKCs and nPKCs have the ability to bind phorbol esters and DAG. As mentioned
above, recent studies revealed that DAG/phorbol ester-responsive C1 domains are
also present in PKDs, MRCKs, DAG-kinases, Rac-GAPs, RasGRPs, and Munc-13s.
A distinctive aspect of most C1 domain-containing proteins is their ability to
redistribute to membranes in response to phorbol esters or to stimulation of receptors
that couple to DAG generation. A continuous hydrophobic surface generated by the
phorbol ester or DAG facilitates the insertion of the C1 domain into lipid bilayers
(Figure 1.5), which in the case of cPKCs and nPKCs is followed by a conformational
rearrangement that leads to kinase activation.
The C1 domain of chimaerins shows a ~40% identity to those in PKCs.
[3H]PBDu binding assays revealed that β2-chimaerin binds the ligand with high
affinity in the presence of PS vesicles. The dissociation constant (Kd) value for β2chimaerin is approximately 1 nM (25), which is in the same range as those for cPKCs
and nPKCs (85). However, structure-activity relationship studies demonstrated
remarkable differences between PKCα and β2-chimaerin for the ligand

14

Figure 1. 5 Structures of cysteine-rich domains (C1 domains) from PKCδ and β2chimaerin. Adapted from: Ron and Kazanietz, FASEB J. (1999) 13: 1658-1676.
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thymeleatoxin. Thymeleatoxin showed significant preference for PKCα relative to
β2-chimaerin (about 60-fold). Other phorbol esters, such as 12-deoxyphorbol 13phenylacetate, 12-deoxyphorbol 13-acetate, and mezerein also showed moderate
preference for PKCα compared to β2-chimaerin. The diacylglycerol 1-oleoyl-2acetyl-glecerol (OAG) and the indole alkaloid (-)-indolactam V showed similar
affinities for both PKCα and β2-chimaerin (26).

DAG/phorbol ester receptors: protein-protein interactions
Accumulating evidence suggests that PKC isozymes differ in their tissue
distribution, substrate specificity, cofactor requirements, and subcellular localization
(46). Specificity of PKC function is thought to be achieved by their association with
specific interacting proteins. PKC isozymes have been reported to localize to various
subcellular compartments (68, 126), including plasma membrane (69, 134), Golgi
apparatus (98-100), mitochondria (113), nuclear membrane (128), and the nucleus
(202). Many anchoring proteins have been identified for PKC isozymes, and they are
termed receptor for activated C-kinases (RACKs) or receptor for inactivated Ckinases (53), depending if they bind to active or inactive PKCs, respectively (45, 53).
Several PKC-interacting proteins that associate with the C1 domains in PKC
isozymes have been identified, which modulate either activity or cellular localization.
An early study reported that the C1 and pseudosubstrate domains in PKCε bind to the
tyrosine kinase Btk PH domain. Upon PMA treatment, the PKC-Btk interaction was
inhibited (196). Recently, Chen et al. demonstrated that localization of PKCβII to
centrosomes, organelles that play a central role in microtubule organization, spindle
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formation and cytokinesis, is regulated by association with the scaffolding protein
pericentrin via the PKCβII C1a domain. Disruption of this interaction releases
PKCβII from the centrosomes, causing inhibition of spindle formation and cell
division (34). The cell matrix protein fascin was also shown to interact with the
PKCα C1b domain. The interaction is dependent on PKCα activity, and inhibition of
the interaction leads to cell migration on fibronectin and fascin protrusions, arguing
that the PKCα-fascin complex is key for regulating cell motility (4). The PKCγ C1b
domain binds 14-3-3τ (135). This interaction is important in the regulation of Gap
junction activity by PKCγ. An interaction between the PKD1 C1 domain and 14-3-3τ
in T cells negatively regulates PKD1 functions (78). Early experiments using PKCε
truncated mutants revealed that C1 domains in PKCε played a role in perinuclear
targeting. PKCε was reported to associate with Golgi membranes via its C1 domains
and to modulate Golgi functions (98, 99). Mochly-Rosen’s group demonstrated that
β’-COP is a PKCε-selective RACK (45). β’-COP is COP I (coat protein I) coatomer
complex protein that is essential for Golgi budding and vesicular trafficking. Studies
have linked PKC to the control of constitutive membrane trafficking and Golgi
function (23, 30, 48, 87, 160, 194). Recently, Sunesson et al. reported that PKCε C1b
binds to peripherin leading to apoptosis in neuroblastoma cells (169). Moreover,
PKCε also was found to bind specifically to filamentous actin in a phorbol esterdependent manner, suggesting that the interaction is dependent on the C1 domain.
Taken together, all of these studies highlight the relevance of C1 domains in proteinprotein interactions in addition to their well-established phorbol ester/DAG-binding
properties.
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Chimaerins: high affinity DAG/phorbol ester receptors
In 1990 Lim and his coworkers identified a novel phorbol ester receptor highly
expressed in brain. n-chimaerin (later renamed α1-chimaerin) resembles a “chimaera”
between the regulatory region of PKC isozymes and BCR, the breakpoint cluster
region protein involved in the translocation of Philadelphia chromosome in chronic
myelogenous leukemia (1, 75). The chimaerin family of phorbol ester receptors
comprises four isozymes (α1 (n)-, α2-, β1 and β2-chimaerins). In addition to a single
C1 domain, chimaerins possess a C-terminal domain with Rac-GAP (GTPaseactivating protein) activity that specifically accelerates GTP hydrolysis into GDP
from Rac, a small GTPase that is involved in actin cytoskeleton organization, cell
cycle progression, malignant transformation, adhesion, migration and metastasis (79)
(Figure 1.6). Rac guanine nucleotide exchange factors such as Tiam 1 play a role in
cell invasion and cell-cell adhesion, arguing for a key role for Rac in the metastatic
cascade (123, 141, 189). Indeed, accumulating evidence revealed that Rac is involved
in the progression of many tumors, such as glioma, lung, prostate and breast cancer
(133). α2- and β2-chimaerin have an extra N-terminal SH2 domain. α1 and α2chimaerin are alternative splicing products of the α-chimaerin gene (CHN1), while β1
and β2-chimaerin are splicing products of the β-chimaerin gene (CHN2). α2- and β2chimaerin are highly conserved, sharing 82% identity with higher degree of similarity
among individual domains. α1- and α2-chimaerins are highly expressed in brain,
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Figure 1.6 Switches between Rac-GDP and Rac-GTP.
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whereas α2-chimaerin expresses mainly in the brain cortex (74). β1-chimaerin is
expressed in the testis (103). β2-chimaerin is ubiquitously expressed (102).
In vitro binding assays using [3H]PDBu as a radioligand revealed that β2chimaerin is a high affinity phorbol ester receptor in the presence of the acidic
phospholipid PS (25). DAG lactones, synthetic DAG mimetics in which the glycerol
head of DAG has been constrained into a lactone ring to offer rigidity and stability,
alos have high affinity for β2-chimaerin.
Subcellular fractionation assays in COS cells demonstrated that PMA causes β2chimaerin translocation from the cytosol to a particulate fraction in a dose-dependent
and time-dependent manner (27). Deletion or mutation of critical amino acids in the
C1 domain, such as Cys246, abolishes β2-chimaerin translocation, auguing that the
C1 domain in β2-chimaerin is essential for PMA-induced translocation (27). Using
GFP-fused β2-chimaerin expressed in COS or HeLa cells, our laboratory showed
redistribution to the plasma membrane followed by a significant perinuclear
accumulation in response to phorbol esters, while no translocation of GFP-β2chimaerin (C246A) was observed (Figure 1.7). Interestingly, unlike α2- and β2chimaerins, α1- and β1-chimaerins were found predominantly in the particulate
fraction even in the absence of PMA, suggesting that the SH2 domain in α2- and β2chimaerins plays a role in intracellular targeting (29). Furthermore, microscopy
images

demonstrated

that

GFP-α1-

and

GFP-β1-chimaerins

were

found

predominantly in the perinuclear region of cells (27).
To assess the regulation of β2-chimaerin in a physiological context, in previous
work that I carried out in the Kazanietz lab, I used epidermal growth factor receptor
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Figure 1.7. Time-lapse images of GFP-β2-chimaerin (wt) or GFP-β2-chimaerin (C246A)
localization after PMA (3 μM) treatment.
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(EGFR) activation as a paradigm for chimaerin activation since it couples to PLCγ to
generate DAG. EGFR activation also leads to Rac activation (182, 184). In that study
we found that EGF promotes a transient translocation of β2-chimaerin to the plasma
membrane. The PLCγ inhibitor U73122 as well as RNAi depletion of PLCγ impair
the translocation of β2-chimaerin to plasma membrane, implying that β2-chimaerin is
a downstream effector of EGFR. Moreover, we found that the C1 domain in β2chimaerin is required for translocation since a C1 domain mutant (C246A-β2chimaerin) does not translocate to plasma membrane in response to EGF.
On the other hand, we also demonstrated that β2-chimaerin associates with RacGTP in response to EGF or PMA. First, using GST pull-down assays, we
demonstrated that GST-tagged constitutively active V12Rac1 strongly associates with
β2-chimaerin, whereas the dominant-negative N17Rac1 does not. Second, confocal
imaging studies revealed that β2-chimaerin co-localizes with V12Rac1 in the plasma
membrane. Lastly, I developed a fluorescence resonance energy transfer (FRET)
approach that was instrumental to demonstrate a significant interaction between CFPRac1 and YFP-β2-chimaerin on the cell periphery upon EGFR stimulation. The
interaction occurs as early as 1 min after EGF stimulation and is transient, returning
to baseline after ~5 minutes (184).
In collaboration with Dr. Jim Hurley at the NIH, our laboratory determined the 3-D
structure of β2-chimaerin (29). The crystal structure revealed that extensive
intramolecular contacts in β2-chimaerin keep the protein in a “closed” conformation.
The C1 domain of β2-chimaerin is buried at the heart of the structure and interacts
with the N-terminus, the SH2 domain, the SH2-C1 domain linker and the Rac-GAP
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domain. In addition to occluding the DAG/phorbol ester binding site, the N-terminus,
the SH2 domain, the SH2-C1 domain linker and the Rac-GAP domain form
hydrophobic interactions with a ring of hydrophobic side chains located around the
C1 domain (29). These side chains are thought to be very important for the insertion
of the C1 domain into the membrane. This may explain why β2-chimaerin requires
high concentration of phorbol ester to translocate to the plasma membrane as well as
to interact with Rac. Mutations of residues thought to be important to keep
intramolecular interactions showed enhanced PMA-induced translocation and
stronger Rac-GAP activity. Based on all the experimental data and 3-D structure
(Figure 1.8), our laboratory proposed a model for translocation and activation of β2chimaerin. Inactivated β2-chimaerin exists in a “closed “ conformation in which
extensive intramolecular interactions serve to occlude the DAG/phorbol ester-binding
site of the C1 domain and the Rac-GAP domain. Upon PMA treatment or DAG
generation by growth factor receptor stimulation, β2-chimaerin undergoes a
conformational rearrangement and acquires an “open” conformation. Large
hydrophobic patches in “open” β2-chimaerin contribute to aligning the protein at the
membrane (29, 184)

Chimaerins as Rac-GAPs:
In vitro assays demonstrated that β2-chimaerin has GAP activity towards the small
G-protein Rac1, but not Cdc42 or RhoA, indicating that β2-chimaerin is a Rac
specific GAP (28). Ectopic expression of β2-chimaerin in cells significantly reduced
active Rac-GTP levels under both normal growth conditions or upon stimulation by
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A.

B.

C.

Figure 1.8 Crystal structure of β2-chimaerin. A. Structures of SH2 (red), C1 (blue)
and Rac-GAP (green) domains. B. Inactive “closed” conformation of β2-chimaerin
C. Active “open” conformation of β2-chimaerin. Adapted from: Canagarajah et al.
Cell (2004) 119: 407-418.
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EGF or PMA, and the effect was dependent upon a functional C-terminal GAP
domain. On the other hand, Cdc42-GTP or RhoA-GTP levels were not affected by
overexpression of β2-chimaerin, suggesting that it acts as a specific Rac-GAP in
cells. In line with those findings, several studies demonstrated that β2-chimaerin is an
important regulator of Rac signaling in cells and possibly implicated in cancer
progression. β2-chimaerin was found to be down-regulated in high-grade
astrocytomas (anaplastic astrocytomas and glioblastomas) when compared with
normal brain and low-grade astrocytomas (199). A subsequent study from our
laboratory demonstrated that β2-chimaerin mRNA levels are significantly downregulated in human breast cancer cell lines and breast tumors (195). Overexpression
of β2-chimaerin in MCF-7 breast carcinoma cells leads to inhibition of cell
proliferation accompanied by decreased Rac-GTP, cyclin D1 and phosphorylated
retinoblastoma protein (pRb) levels, whereas expression of V12Rac1 restored the
proliferation of these cells (195). β2-chimaerin also inhibits EGF-mediated effects,
including actin cytoskeleton reorganization and cell migration. The inhibitory effects
of β2-chimaerin on cell migration could be restored by overexpression of V12Rac1
(184). In Jurkat T-cells, expression of β2-chimaerin also impairs PMA-induced actin
polymerization, CXCL12-induced Rac activation, cell spreading and adhesion to
VCAM-1 (159). I previously demonstrated that EGF-induced activation of Rac is
potentiated and prolonged when β2-chimaerin is knocked-down using RNAi,
suggesting that β2-chimaerin acts as a mechanism for limiting the intensity and
duration of Rac signaling (184). Similar results were reported later in NIH3T3 cells
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upon PDGF stimulation, suggesting a role for β2-chimaerin in limiting the strength of
Rac-GTP activation in response to growth factors (197).
Several in vivo models have been used to elucidate the physiological role of
chimaerins. In our laboratory we have cloned the zebrafish chimaerin gene, which
encodes a protein highly homologous to α2- and β2-chimaerin, with 86% and 74%
amino acid identity, respectively. The zebrafish chimaerin behaves similarly to the
human chimaerins, as it translocates to the plasma membrane in response to PMA and
possesses Rac-GAP activity. Depletion of chimaerin by injection of antisense
morpholino RNAs into zebrafish embryos at one cell stage leads to significant
developmental

defects.

Chimaerin-deficient

zebrafish

embryo

displayed

hyperactivation of Rac and faster migration through epiboly, which results in
enlarged tailbuds. Interestingly, these defects can be rescued by microinjection of
chimaerin mRNA into the yolk syncytial layer. These results suggested that chimaerin
is critical for regulating Rac-mediated migration during zebrafish development (101).
Studies in Drosophila also revealed an important role for chimaerin in the modulation
of Rac signaling during development. RhoGAP5a, a single ortholog for chimaerins in
Drosophila that shares 37% identity with human β2-chimaerin, is expressed in the
interommatidial precursor cells of the developing fly eye. Depletion of RhoGAP5A in
these cells increases numbers of cells and leads to aberrant cell-cell contacts.
RhoGAP5A was also linked to EGFR signaling in the fly eye since knockdown of
RhoGAP5A enhances ERK activation, implying that RhoGAP5A interacts with Rac
to regulate EGFR-ERK signaling (22).
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Experiments using α2-chimaerin knockout mice established an important role for
α2-chimaerin in axon guidance and growth cone collapse. Mice lacking α-chimaerin
exhibit a hopping phenotype that is similar to that of EphA4 receptor-deficient mice.
EphA4 repulsive signaling induces growth cone collapse that keeps corticospinal tract
(CST) axons from crossing the midline. Axons from mice lacking α-chimaerin are
unresponsive to these repulsive cues, which results in aberrant midline crossing of
spinal cord projections and altered motor circuit formation. These results
demonstrated that α-chimaerin GAP activity for inactivation of Rac is required for
EphA4-induced growth cone collapse. Interestingly, Nck1-lacking mice also develop
a similar phenotype to that of EphA4 and α2-chimaerin knockout mice, suggesting
that Nck1 may be a critical component in the EphA4 receptor-chimaerin signaling
pathway (12, 55, 83, 155, 185). One of the most remarkable recent findings has been
that human CHN1 mutations that hyperactivate α2-chimaerin are the cause of
Duane's retraction syndrome (DRS), which is a complex congenital eye movement
disorder caused by aberrant innervation of the extraocular muscles by axons of
brainstem motor neurons (125). Patients with DRS have substitution mutations in α2chimaerin that lead to hyperactive proteins with enhanced GAP activity as well as
enhanced membrane translocation (125). Remarkably, many of these mutations in
α2-chimaerin are equivalent to those leading to an “open“ conformation predicted in
our structural studies of β2-chimaerin. Indeed, we found that mutation of Ile126
residue, which is frequently mutated in DRS, confers enhanced GAP activity and
translocation in cells (43).
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Identification of p23/Tmp21 as a chimaerin-interacting protein
In early studies carried out in the Kazanietz lab, I identified a chimaerin-binding
protein using a yeast two-hybrid approach. This screen established that p23/Tmp21, a
type I transmembrane protein involved in vesicle transport and protein trafficking,
interacts with both α- and β-chimaerins. Using a series of truncation mutants, I
further established that the C1 domain in chimaerins is required for the interaction.
Confocal microscopy analysis demonstrated that chimaerins co-localize with
p23/Tmp21 in the perinuclear region. Mutations or deletion of the C1 domain
abolished the chimaerin perinuclear localization. This suggested that p23/Tmp21
might act as an anchoring protein for chimaerins. Interestingly, p23/Tmp21 inhibits
β2-chimaerin Rac-GAP activity in cells when co-expressed with β2-chimaerin,
suggesting that p23/Tmp21 may limit β2-chimaerin Rac-GAP activity by
sequestering it in the perinuclear region (181). More recently, our laboratory found
that β2-chimaerin function is regulated by another DAG/phorbol ester-regulated
protein, PKCδ. Ser169 in β2-chimaerin becomes phosphorylated by PKCδ upon
treatment with PMA or EGF. This post-translational modification prevents β2chimaerin membrane relocalization in response to stimuli and represents a means of
limiting the strength of β2-chimaerin Rac-GAP activity, suggesting dual roles of
DAG signaling pathway in regulating β2-chimaerin functions. By summarizing all
the studies from our laboratory, we propose the following updated model for
regulation and activation of β2-chimaerin (Figure 1.9).
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Figure 1.9 Model of activation and regulation of β2-chimaerin upon growth factor
stimulation.
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Scope and significance of my thesis research
The overall objective of my dissertation research is to investigate the regulation
and function of C1 domain-containing proteins in different paradigms. My focus will
be primarily on β2-chimaerin and nPKCs.
In the case of β2-chimaerin, I have previously identified that it can interact with
p23/Tmp21, an ER/Golgi cargo protein widely implicated in trafficking from the
intermediate compartment to the Golgi (16, 18, 163). In the present studies, I
elucidate how β2-chimaerin interacts with p23/Tmp21. A deletional analysis in αand β-chimaerins revealed that the C1 domain is the p23/Tmp21-interacting motif
(181). Our biochemical and imaging studies strongly support the formation of a
chimaerin-p23/Tmp21 complex in cells (181), suggesting that p23/Tmp21 actually
serves as a perinuclear anchoring protein for chimaerin Rac-GAPs. It is still unclear
which amino acid(s) in the β2-chimaerin C1 domain is (are) crucial for the
interaction. It also remains to be determined if p23/Tmp21 associates with other
proteins possessing C1 domains to drive their perinuclear translocation. This is
relevant because proteins with C1 domains, such as PKCε, have been shown to
localize at the Golgi. I will focus on the ability of C1 domains to dictate intracellular
localization via protein-protein interactions, which expands our view that these
domains act primarily as lipid-binding motifs and also highlights the complexities of
DAG signaling. These studies represent the core of Chapter 2.
It is well established that PMA and related analogs induce apoptosis in androgendependent prostate cancer cells, an effect primarily mediated by PKCδ. Βased upon
the finding that p23/Tmp21 could interact with PKC isozymes, chimaerins as well as
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RasGRP, I investigated whether PKCδ could directly associate with p23/Tmp21 in
LNCaP prostate cancer cells, and assessed the functional consequences of these
findings. In Chapter 3, I demonstrate that p23/Tmp21 directly associates with PKCδ
in LNCaP prostate cancer cells and present data showing that p23/Tmp21 acts as an
anchoring protein that negatively regulates the apoptotic effects of PMA. Our
findings reveal a novel function for p23/Tmp21 in DAG signaling, which is
independent of its previous well-established role acting as a vesicle trafficking
protein.
Many studies have reported that membrane-related signaling cascades might play
important roles in controlling radiation-induced cell death. In Chapter 4 of my
dissertation I present studies on the roles of PKC isozymes in the resistance to γirradiation in PC3 prostate cancer cells. Most prostate cancer cells express three
DAG/phorbol ester-responsive protein kinase C (PKC) isozymes: PKCα, PKCδ and
PKCε. The role of individual PKC isozymes in prostate cancer radiosensitivity
remains elusive. My results reveal that PKCε, but not PKCα and PKCδ, confers
radioresistance to androgen-independent prostate cancer cells. Moreover, C1 domain
mediated translocation of PKCε by γ-irradiation represents the key event in this
paradigm.
In summary, my thesis will present novel findings on the regulation and function
of C1 domain-containing proteins: β2-chimaerin, PKCδ, and PKCε.
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CHAPTER 2
p23/Tmp21 differentially targets the Rac-GAP β2-chimaerin and
protein kinase C via their C1 domains

This work was published in:
Molecular Biology of the Cell. Epub February 17, 2010 as 10.1091/mbc. E09-080735

32

ABSTRACT
The C1 domains in PKC isozymes and other signaling molecules are responsible
for binding the lipid second messenger DAG and phorbol esters, and mediate
translocation to membranes. Previous studies revealed that the C1 domain in α- and
β-chimaerins, DAG-regulated Rac-GAPs, interacts with the ER/Golgi protein
p23/Tmp21. Here we found that p23/Tmp21 acts as a C1 domain-docking protein that
mediates perinuclear translocation of β2-chimaerin. Glu227 and Leu248 in the β2chimaerin C1 domain are crucial for binding p23/Tmp21 and perinuclear targeting.
Interestingly, isolated C1 domains from individual PKC isozymes differentially
interact with p23/Tmp21. In the case of PKCε, it interacts with p23/Tmp21
specifically via its C1b domain, however this association is lost in response to
phorbol esters. These results demonstrate that p23/Tmp21 acts as an anchor that
distinctively modulates compartmentalization of C1 domain-containing proteins, and
it plays an essential role in β2-chimaerin relocalization. Our study also highlights the
relevance of C1 domains in protein-protein interactions in addition to their wellestablished lipid-binding properties.
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INTRODUCTION
C1 domains are 50-51 amino acid long cysteine-rich motifs originally identified
in PKC as the binding sites for the lipid second messenger DAG and the phorbol ester
tumor

promoters.

These

domains

contain

the

characteristic

motif

HX12CX2CX13/14CX2CX4HX2CX7C, where H is His, C is Cys, and X is any other
amino acid. X-ray crystallography analysis revealed that C1 domains are compact
globular structures coordinated through binding of two Zn2+ ions to conserved Cys
and His residues. While this motif is duplicated in tandem (C1a and C1b domains) in
classical PKCs (cPKCα, βI, βII and γ) and novel PKCs (nPKCδ, ε, η and θ), a single
copy is present in phorbol ester/DAG unresponsive atypical PKC isozymes (aPKCζ,
ι/λ)(122, 134). C1 domains capable of binding phorbol esters and DAG are also
present in other protein kinases such as protein kinase D isozymes (PKDs) and
Myotonic Dystrophy Kinase-related Cdc42-binding Kinase (MRCK), lipid kinases
(DAG-kinases), GTPase activating proteins (α- and β-chimaerin Rac-GAPs), guanine
nucleotide exchange factors (RasGRP GEFs), and scaffolding proteins (Munc-13s)(1,
13, 25, 39, 52, 75, 117, 156, 178).
A distinctive feature of most phorbol ester receptors with C1 domains is their
ability to redistribute to membranes in response to stimulation of receptors that couple
to DAG generation or phorbol esters. A continuous hydrophobic surface generated by
the phorbol ester or DAG facilitates the insertion of the C1 domain into lipid bilayers,
which in the case of cPKCs and nPKCs is followed by a conformational
rearrangement that leads to kinase activation (46, 151, 201). It is noteworthy that
upon activation PKCs relocalize not only to plasma membrane but also to other
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intracellular compartments including the nuclear membrane (128), perinuclear
structures (80), and mitochondria (114). A high degree of isozyme selectivity for
translocation to different intracellular compartments appears to exist (126). For
example, early studies established that PKCε localizes to the Golgi complex in NIH
3T3 cells via the C1 domain (98, 100). Moreover, a recent study in neuroblastoma
SK-N-BE(2)C cells revealed that mutation of specific residues in the PKCε C1b
domain impairs its perinuclear localization without affecting its translocation to the
plasma membrane in response to the C1 domain ligand PMA (153).
We have previously established that α2- and β2-chimaerins translocate both to
the plasma membrane and the perinuclear region in response to PMA or DAG
analogs via the C1 domain (27). Deletion of the C1 domain or mutations of key
amino acids implicated in phorbol ester binding impairs both the peripheral and
perinuclear translocation of chimaerins, thus arguing that the C1 domain is essential
for chimaerin intracellular targeting (25-27, 184). Other “non-kinase” phorbol
ester/DAG receptors such as RasGRP1/3 and Munc-13 also translocate to the plasma
membrane and Golgi in response to PMA via their C1 domains (28, 165). The
molecular basis for the translocation of proteins with C1 domains is only partially
understood. Speculation has been that protein-protein interactions are key factors for
determining their selective intracellular relocalization, and studies have indeed
identified numerous PKC interactors that dictate compartmentalization through
binding to unique motifs present in individual isozymes, such as the receptors for
activated C-kinases (RACKs) (45). Interactions may require a conformational
rearrangement that exposes the protein binding domain (127). Although these
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mechanisms have been extensively studied for PKC isozymes, the involvement of
protein partners in targeting chimaerin Rac-GAPs has not been established yet.
In a previous yeast two-hybrid screening I identified the Golgi/ER protein
p23/Tmp21 (p24δ) as a chimaerin-interacting protein (181). p23/Tmp21, a type I
transmembrane protein, belongs to the p24 protein family that has been widely
implicated in trafficking from the intermediate compartment to the Golgi (16, 18,
163). A deletional analysis in α- and β-chimaerins revealed the C1 domain as the
p23/Tmp21-interacting motif (181). Biochemical and imaging studies strongly
support the formation of a chimaerin-p23/Tmp21 complex in cells (181). We
hypothesize that p23/Tmp21 might serve as a perinuclear anchoring protein for
chimaerin Rac-GAPs. Moreover, p23/Tmp21 might also associate with other proteins
containing C1 domains to drive their perinuclear translocation. This is relevant
because proteins with C1 domains, such as PKCε, have been shown to localize at the
Golgi.
In this Chapter I present data demonstrating that p23/Tmp21 is required for the
perinuclear translocation of β2-chimaerin. This Rac-GAP indeed fails to redistribute
to the perinuclear compartment in p23/Tmp21-deficient cells. I also identified key
residues in the β2-chimaerin C1 domain that specifically mediate its association with
p23/Tmp21 and translocation to the perinuclear compartment. Interestingly,
p23/Tmp21 also interacts with other C1 domains in isolation, including C1 domains
from PKC isozymes. Our results support the notion that C1 domains act not only as
lipid binding motifs but can also mediate protein-protein interactions that determine
selective intracellular compartmentalization.
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RESULTS
The C1 domain of β2-chimaerin and C1b domain of PKCε interact with
p23/Tmp21
In previous studies I identified p23/Tmp21, a type I transmembrane protein highly
enriched in the ER and Golgi, as an α- and β-chimaerin-interacting protein. A
deletional analysis established that interaction with p23/Tmp21 occurs through a
region that encompasses the chimaerin C1 domain (181). Since PKCε was shown to
localize at the perinuclear region via its C1 domain region (153), we speculated that
C1a and/or C1b domains in PKCε may interact with p23/Tmp21. To address this
issue we first examined whether the C1 region of PKCε, which include both C1a and
C1b domains (C1εa-b), interacts with p23/Tmp21 in a yeast two-hybrid system. A
pLexA construct encoding C1εa-b was generated (Figure 2.1A) and co-transformed
with pB42AD-p23/Tmp21 (HA-tagged, aa 108-208, a fragment that interacts with
chimaerins) into EGY48 yeast containing p8OP-LacZ vector (181). The triple vectors
co-transformants were selected by plating the yeast into SD/-Ura/-His/-Trp dropout
plates. pLexA-fused proteins were expressed in both galactose/raffinose (+Gal/Raf)
plates and glucose plates (-Gal/Raf), while HA-tagged pB42AD-p23/Tmp21 (aa 108208) was only expressed in galactose/raffinose induction plates (data not shown).
Figure 2.1B shows that both the β2-chimaerin C1 domain (C1β2-ch) and C1εa-b
strongly interact with p23/Tmp21, as revealed by the induction of the LacZ reporter
(blue color). These interactions were also detected using a liquid β-galactosidase
assay (Figure 2.1C).
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Studies have determined that C1εb but not C1εa is essential for Golgi localization
in neuroblastoma SK-N-BE(2)C cells (153), suggesting a differential involvement of
each domain in perinuclear targeting. We therefore generated pLexA-fused C1εa and
C1εb constructs (Figure 2.1A), co-transformed each of them with pB42ADp23/Tmp21 into the EGY48 (p8OP-LacZ) yeast, and expressed both proteins in
+Gal/Raf plates. Interestingly, a strong association was observed with C1εb, while
C1εa failed to interact with p23/Tmp21 (Figure 2.1B and 2.1C). To further establish
whether C1 domain specificity exists, we generated pLexA constructs encoding C1
domains of aPKCζ (C1ζ), PKCα (C1α), PKCδ (C1δ), and RasGRP1. While C1ζ
failed to interact with p23/Tmp21 in the yeast two-hybrid assay (Figure 2.1B),
association was detected for C1α and C1δ, and the C1 domain of the Ras/Rap1
exchange factor RasGRP1 weakly interacted with p23/Tmp21 (Figure 2.2A, 2.2B,
and 2.2C).
Next, we determined the intracellular localization of C1β2-ch, C1εa, and C1εb
domains in mammalian cells. C1 domains were expressed as GFP-fusion proteins in
HeLa cells, and localization examined by confocal microscopy (Figure 2.1D).
Remarkably, individual C1 domains exhibited distinct intracellular localization.
While GFP-C1εa distributed throughout the cell and had no obvious perinuclear
localization, as previously reported in SK-N-BE(2)C cells (153), GFP-C1εb and GFPC1β2-ch showed a characteristic perinuclear localization. GFP-C1ζ displayed a
strong nuclear localization when expressed in HeLa cells but no obvious perinuclear
staining. Thus, C1 domains, when expressed in isolation, have unique localization
properties.
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Next, we examined whether different C1 domains co-localize with p23/Tmp21.
HeLa cells were co-transfected with pcDNA3-V5-p23/Tmp21 together with plasmids
encoding different C1 domains fused to GFP, and co-localization determined by
confocal microscopy. As shown in Figure 2.3, both GFP-C1εb and GFP-C1β2-ch colocalized with p23/Tmp21, as judged by the yellow color observed in the overlapped
images. Quantification using ImageJ and analysis using a Pearson’s correlation
coefficient (Rr) confirmed these results. In contrast, neither GFP-C1εa nor GFP-C1ζ
showed any obvious co-localization with p23/Tmp21. GFP alone also failed to colocalize with p23/Tmp21 in HeLa cells. We also found that full-length PKCα,
PKCδ and RasGRP1 have some degree of co-localization with P23/Tmp21 (Figure
2.2D). These results are in agreement with those observed in the yeast two-hybrid
analysis, and reveal unique patterns of intracellular localization and protein
interactions for discrete C1 domains.
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Figure 2.1 Differential interaction of C1 domains with p23/Tmp21. A. Schematic representation of
C1εa-b, C1εa, C1εb, C1ζ, or C1β2-ch domain fused to pLexA. B. EGY48 yeast (containing 8op-LacZ
vector) was co-transformed with pLexA encoding C1εa-b, C1εa, C1εb, C1ζ, or C1β2-ch domain, and
pB42AD-HA-tagged p23/Tmp21 (aa 108-208). Assay of β-galactosidase activity on induction (upper
panel) or no-induction (lower panel) plates was carried out 72 h after transformation. Gal/Raf,
galactosidase/raffinose. C. Assay of β-galactosidase activity in liquid cultures using ONPG as a
substrate. Results were expressed as mean ± S.D. (n=3). D. GFP-PKCεC1b domain localizes in the
perinuclear region. HeLa cells were transfected with pEGFP-C1εa, C1εb, C1ζ, or C1β2-ch. Forty-eight
h later, cells were fixed and localization examined by confocal microscopy. Bar, 10 μm. All
experiments have been performed at least three times with similar results.
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Figure 2.2 Binding of C1 domains to p23/Tmp21. EGY48 yeast (containing 8op-LacZ vector) was cotransformed with pLexA-fused C1 domains from PKCα (C1αa-b), PKCε (C1εa-b), PKCδ (C1δa-b),
PKCζ (C1ζ), RasGRP1 (C1RasGRP1), or β2-chimaerin (C1β2-ch), and pB42AD-HA-tagged
p23/Tmp21 (aa 108-208). A. Alignment of PKCα, PKCδ, PKCε C1b, RasGRP1, and β2-chimaerin C1
domains. Positions 15 and 36 in C1 domains are indicated with arrows. B. Schematic representation of
C1 domains fused to pLexA. C. Assay of β-galactosidase activity on induction (upper panel) or noinduction (lower panel) plates, carried out 72 h after transformation. Gal/Raf, galactosidase/raffinose.
Two additional experiments gave similar results. D. HeLa cells were co-transfected with plasmids
encoding GFP-PKCα, GFP-PKCδ, GFP-PKCε, GFP-RasGRP1 or GFP-β2-chimaerin, and pcDNA3.1V5-p23/Tmp21. Forty-eight h later, cells were fixed and co-localization examined by confocal
microscopy. Bar, 10 μm. All experiments have been performed at least three times with similar results.
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Figure 2.3 Co-localization of GFP-fused PKCε C1b and β2-chimaerin C1 domains
with p23/Tmp21. HeLa cells were co-transfected with pEGFP-fused C1εa, C1εb, C1ζ,
or C1β2-ch (or empty vector) and V5-tagged full-length pcDNA3-p23/Tmp21. Fortyeight h later, cells were fixed and stained with an anti-V5 antibody, and localization
examined by confocal microscopy. Co-localization images and Pearson’s correlation
coefficient (Rr) were generated by Image J. Similar results were observed at least in 3
independent experiments. Bar, 10 μm.
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Co-localization of full-length PKCε and p23/Tmp21
Experiments carried out with isolated C1 domains established proof-of-principle
for differential targeting, but may or may not reflect what occurs with intact proteins
in cells. Therefore, we next decided to investigate the association of full-length β2chimaerin and PKCε with p23/Tmp21 in mammalian cells. COS-1 cells were
transfected with pEBG control vector (which encodes GST alone) (181) or pEBGp23/Tmp21. After 24 h, cells were infected with adenoviruses for either fulllength PKCε or full-length β2-chimaerin, and 24 h later subject to GST pull-down
using glutathione Sepharose 4B beads. As shown in Figure 2.4A (left panel), and in
agreement with our previous study (27, 181), β2-chimaerin was detected in complex
with GST-p23/Tmp21 but not with GST. β2-chimaerin was shown to translocate to
the perinuclear compartment in response to C1 domain ligands such as PMA. This
effect was lost when key residues in the C1 domain are mutated but was not affected
by the pan-PKC inhibitor GF 109203X, suggesting that the PMA effect was not
mediated by PKCs (27, 181). Figure 2.4A (left panel) also shows that the association
of β2-chimaerin with GST-p23/Tmp21 was markedly enhanced by PMA. A
densitometric analysis revealed that PMA caused a ~7-fold increase in the association
of β2-chimaerin with p23/Tmp21 (Figure 2.4A, right panel). The association between
β2-chimaerin and p23/Tmp21 can also be enhanced in cells growing in serum and in
response to EGF treatment, although in this last case to a lower extent than that
observed with PMA (Figure 2.5). Interestingly, PKCε can be readily detected in GSTp23/Tmp21 precipitates, whereas it cannot be pulled down by GST alone, an
indication that PKCε and p23/Tmp21 exist as a complex. However, in contrast to β243

chimaerin, PKCε dissociated from p23/Tmp21 when cells were treated with PMA
(Figure 2.4B).
The distinct association pattern of PKCε and β2-chimaerin with p23/Tmp21
prompted us to examine whether they differentially re-localize in response to phorbol
ester treatment. HeLa cells expressing GFP-PKCε or GFP-β2-chimaerin (full-length)
were treated with either PMA or vehicle, and localization examined by confocal
microscopy. Like β2-chimaerin, PKCε displayed some degree of co-localization with
p23/Tmp21 in the perinuclear region of vehicle-treated cells (Rr=0.25). However, a
remarkably distinct pattern of translocation for each protein was observed in response
to PMA: while β2-chimaerin redistributed primarily to the perinuclear compartment
and co-localized with p23/Tmp21 in response to PMA (Rr increases from 0.16 to
0.42) (plasma membrane localization can be also detected)(27, 181), PKCε fully
translocated to the cell periphery. Coincidentally, no perinuclear PKCε or colocalization with p23/Tmp21 could be observed in PMA-treated cells (Rr= -0.04)
(Figure 2.4C). These results argue for a differential interaction of PKCε and β2chimaerin with p23/Tmp21 in response to stimuli. Moreover, they also suggest that
domain(s) in PKCε other than the C1b domain must have prominent targeting roles.
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Figure 2.4 Differential interaction of PKCε and β2-chimaerin with p23/Tmp21. A
and B. COS-1 cells were transfected with either pEBG (empty vector) or pEBGp23/Tmp21. Twenty-four h later, cells were infected with either HA-β2-chimaerin
adenovirus (MOI=10 pfu/cell) (A) or PKCε adenovirus (MOI=3 pfu/cell) (B). After
twenty-four h, cells were treated with PMA (1 μM) or vehicle for 30 min in the
presence of the PKC inhibitor GF109203X (5 μM) and lysed. GST or GSTp23/Tmp21 proteins were precipitated with glutathione Sepharose 4B beads and
associated HA-β2-chimaerin detected by Western blot using an anti-HA antibody.
Left panel, representative experiments. Right panel, densitometric analysis of three
individual experiments, expressed as fold-change relative to GST-p23/Tmp21 in the
absence (A) or presence (B) of PMA. C. HeLa cells were co-transfected with either
pEGFP-PKCε or pEGFP-β2-chimaerin and pcDNA3.1/V5-p23/Tmp21 (full length).
Forty-eight h later, cells were treated with PMA (1 μM) or vehicle for 30 min, fixed,
and stained with an anti-V5 antibody, and localization examined by confocal
microscopy. Upper panels, green fluorescence from GFP-PKCε or GFP-β2chimaerin; middle panels, red fluorescence from pcDNA3.1/V5-p23/Tmp21; lower
panels, overlapped images. Co-localization images and Pearson’s correlation
coefficient (Rr) were generated by Image J. Similar results were obtained in 3
additional experiments. Bar, 10 μm.
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Figure 2.5 FBS and EGF enhance the association of β2-chimaerin with p23/Tmp21.
COS-1 cells were co-transfected with pEBG-p23/Tmp21 and GFP-β2-chimaerin, and
48 h later either serum-starved for 18 h and stimulated with EGF (100 ng/ml) or left
in 10% FBS. GST-p23/Tmp21 was precipitated with glutathione Sepharose 4B beads
and associated GFP-β2-chimaerin detected by Western blot using an anti-GFP
antibody. A representative example is shown together with a densitometric analysis of
3 independent experiments. *P<0.05 between control (0 min.) vs. treatments.
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p23/Tmp21 depletion impairs perinuclear translocation of β2-chimaerin
To determine the requirement of p23/Tmp21 for β2-chimaerin translocation, we
established p23/Tmp21-depleted HeLa cell lines using lentiviral shRNAs. Three
different lentiviruses were used, and stable cell lines were generated after selection
with puromycin. Figure 2.6A shows that a significant depletion (> 80%) was
observed with shRNA p23/Tmp21 lentiviruses #2 and #3, while shRNA lentivirus #1
was less effective. GFP-β2-chimaerin was expressed in the different stable cell lines,
and its localization in response to PMA was monitored using real-time microscopy.
Figure 2.6B revealed that GFP-β2-chimaerin efficiently translocated to the
perinuclear region (marked with an arrow at 30 min time point) in control cells, as
expected. Likewise, perinuclear translocation was readily detected in cells infected
with p23/Tmp21 shRNA lentivirus #1, in which depletion was minimal. In contrast,
perinuclear translocation of GFP-β2-chimaerin was essentially lost in those cell lines
in which p23/Tmp21 has been markedly depleted. GFP-β2-chimaerin co-localized
with the Cis-Golgi marker GS-28 in the resting state, and PMA treatment enhanced
co-localization (Figure 2.7). Translocation of PKCε to the cell periphery by PMA was
not affected by shRNA p23/Tmp21 depletion (data not shown). These results suggest
that p23/Tmp21 is indispensable for the translocation of β2-chimaerin to the
perinuclear region.
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Figure 2.6 p23/Tmp21 RNAi depletion impairs perinuclear β2-chimaerin translocation. A.
Expression of p23/Tmp21 in HeLa cells stably expressing different p23/Tmp21 shRNAs
(shRNA#1, shRNA#2 and shRNA#3) or control cells. B. Cells were transfected with pEGFPβ2-chimaerin and 48 h later treated with PMA (3 μM) in the presence of GF109203X (5 μM)
Time-lapse images of β2-chimaerin translocation in living cells were captured at different
times after PMA treatment. Perinuclear and periphery translocation were marked with arrows.
Similar results were observed in 3 individual experiments. Bar, 10 μm.
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Figure 2.7 Co-localization of β2-chimaerin with a Golgi marker. HeLa (CTL), HeLa
(shRNA#2) or HeLa (shRNA#3) cells were transfected with pEGFP-β2-chimaerin
and 48 h later treated with vehicle or PMA (3 μM) in the presence of GF109203X (5
μM). After 30 min., cells were fixed, stained with anti-GS28 cis-Golgi marker and
examined by confocal microscopy. Co-localization images and Pearson’s correlation
coefficient (Rr) were generated by Image J. Similar results were observed in 3
separate experiments. Bar, 10 μm.
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Glu227 and Leu248 in the β2-chimaerin C1 domain are critical for translocation
to the perinuclear compartment
In a recent study, Schultz et al. showed that mutation of Asp257 and Met278 in
the PKCε C1b domain (amino acids 15 and 36 in the motif, respectively) abolished
the perinuclear localization of PKCε or its PKCε C1b domain in neuroblastoma cells
(153). We observed that when we mutated both Asp257 and Met278 to Gly in PKCε,
the resulting mutant localized to the plasma membrane even in the absence of PMA
stimulation and does not co-localize with p23/Tmp21 (Figure 2.8). Alignment of
C1εb with C1 domains from both α- and β-chimaerins revealed that an acidic amino
acid in position 15 and a lipophilic amino acid in position 36 of the motif were
conserved (Figure 2.9A). We speculated that Glu227 and Leu248 in β2-chimaerin
might be implicated in perinuclear translocation. Mutants in those positions in β2chimaerin (E227G, L248A, and the double mutant E227G/L248A) were generated,
expressed in HeLa cells as GFP-fused proteins, and their localization in real-time in
response to PMA analyzed by microscopy. Single mutants E227G- and L248A-β2chimaerin showed slightly higher translocation to the plasma membrane compared to
wild-type β2-chimaerin. However, perinuclear translocation after PMA treatment can
still be observed. Conversely, no perinuclear translocation could be observed for the
double mutant E227G/L248A-β2-chimaerin, while plasma membrane fluorescence
was readily detected (Figure 2.9B; videos presented in Supplementary Information of
MBoC paper, Figure 2.14). Therefore, residues in the β2-chimaerin C1 domain
homologous to those in C1εb play a significant role in targeting β2-chimaerin to the
perinuclear compartment.
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The double mutant E227G/L248A-β2-chimaerin fails to interact with
p23/Tmp21
We speculated that the lack of perinuclear translocation of the double mutant
E227G/L248A-β2-chimaerin by PMA was due to its inability to bind p23/Tmp21. We
tested this hypothesis using a yeast two-hybrid assay. pLexA-fused constructs for
E227G-, L248A-, and E227G/L248A-β2-chimaerin C1 domain mutants were
generated

(E227G-C1β2-ch,

L248A-C1β2-ch,

and

E227G/L248A-C1β2-ch

respectively). The pLexA plasmids were co-transformed with pB42AD-p23/Tmp21
into EGY48 (p8OP-LacZ) yeast. As shown in Figure 2.10A, single mutants E227GC1β2-ch and L248A-C1β2-ch retained their ability to bind p23/Tmp21, as revealed
by the induction of the LacZ reporter gene (blue). In contrast, the double mutant
E227G/L248-C1β2-ch was unable to interact with p23/Tmp21. A mutant with a Cys
essential for C1 domain folding mutated to Ala (C246A-C1β2-ch) also failed to
interact with p23/Tmp21, consistent with the lack of translocation of C246A-β2chimaerin in PMA-treated cells (27, 181).
In the next experiments, we determined the association of GFP-β2-chimaerin
mutants with p23/Tmp21 in COS-1 cells using a co-precipitation approach. Cells
were co-transfected with pEBG (empty vector) or pEBG-p23/Tmp21, together with
GFP-β2-chimaerin (wt), GFP-β2-chimaerin (E227G/L248A) or GFP-β2-
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Figure 2.8 PKCε (Asp257/Met278) does not co-localize with p23/Tmp21. HeLa cells
were
co-transfected
with
either
pEGFP-PKCε (wt) or
pEGFPPKCε (Asp257/Met278) and pcDNA3.1/V5-p23/Tmp21 (full-length). Forty-eight h
later, cells were treated with PMA (1 μM) or vehicle for 30 min, fixed, and visualized
by confocal microscopy. Upper panels, green fluorescence from GFP-PKCε or GFPPKCε (Asp257/Met278); middle panels, red fluorescence from pcDNA3.1/V5p23/Tmp21; lower panels, overlapped images. Bar, 10 μm. Similar results were
obtained in 3 independent experiments. Peripheral localization is marked with arrows.
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Figure 2.9 Glu227 and Leu248 in the β2-chimaerin C1 domain are required for perinuclear
translocation. A. Alignment of PKCε C1b and α- and β-chimaerin C1 domains. Positions 15 and 36
are indicated with an arrow. B. HeLa cells were transfected with pEGFP-β2-chimaerin (wt), pEGFPβ2-chimaerin (E227G), pEGFP-β2-chimaerin (L248A), or pEGFP-β2-chimaerin (E227G/L248A).
Forty-eight h later, cells were treated with PMA (3 μM) in the presence of GF109203X (5 μM). Timelapse images of translocation of GFP-β2-chimaerin or its mutants in living cells were captured by
fluorescence microscopy at different times after PMA treatment. Perinuclear and periphery
translocation were marked with arrows. Similar results were observed in 5 independent experiments.
Bar, 10 μm.
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chimaerin (C246A). After 36 h, cells were subject to a pull-down assay using
glutathione Sepharose 4B beads. As shown in Figure 2.10B (left panel), while β2chimaerin (wt) was readily detected in complex with GST-p23/Tmp21, no coprecipitation was observed for β2-chimaerin (E227G/L248A) or β2-chimaerin
(C246A). A quantitative analysis of multiple experiments is presented in Figure
2.10B (right panel).
Furthermore, imaging studies using confocal microscopy showed that while
perinuclear translocation and co-localization with p23/Tmp21 in response to PMA
could still be observed for full-length GFP-β2-chimaerin in which Glu227 and
Leu248 have been mutated individually, the double mutant GFP-E227G/L248A-β2chimaerin was unable to redistribute to the perinuclear compartment or to co-localize
with p23/Tmp21 in cells (Figure 2.11). As also shown in Figure 2.9B, significant
plasma membrane translocation could be detected with the double mutant. In
agreement with previous studies (27, 181), the PMA-unresponsive mutant C246A-β2chimaerin was unable to translocate in response to the phorbol ester.
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Figure 2.10 Glu227 and Leu248 residues in the β2-chimaerin C1 domain are required for
the interaction with p23/Tmp21. A. EGY48 yeast (containing 8op-LacZ vector) was cotransformed with pLexA-β2-chim-C1 (E227G), pLexA-β2-chim-C1 (L248A), pLexA-β2chim-C1 (E227G/L248A), or pLexA-β2-chim-C1 (C246A), and pB42AD-HA-tagged
p23/Tmp21 (aa 108-208). Assay of β-galactosidase activity on induction (upper panel) or noinduction (lower panel) plates was carried out 72 h after transformation. Gal/Raf,
galactosidase/raffinose. B. COS-1 cells were co-transfected with either pEBG (empty vector)
or pEBG-p23/Tmp21 and GFP vector, GFP-β2-chimaerin (wt), GFP-β2-chimaerin
(E227G/L248A) or GFP-β2-chimaerin (C246A). After twenty-four h, cells were lysed. GST
or GST-p23/Tmp21 proteins were precipitated with glutathione Sepharose 4B beads and
associated GFP-fused proteins detected by Western blot using an anti-GFP antibody. Left
panel, representative experiments. Right panel, densitometric analysis of three individual
experiments, expressed as fold-change relative to GST-p23/Tmp21 bound β2-chimaerin (wt).
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Figure 2.11 Co-localization studies of β2-chimaerin mutants and p23/Tmp21. HeLa
cells were co-transfected with pEGFP-β2-chim (wt), pEGFP-β2-chim (C246A),
pEGFP-β2-chim (E227G), pEGFP-β2-chim (L248A), or pEGFP-β2-chim
(E227G/L248A) and V5-tagged pcDNA-p23/Tmp21. Forty-eight h later, cells were
treated with PMA (3 μM) or vehicle for 30 min in the presence of GF 109203X (5
μM). Cells were then washed and visualized by confocal microscopy. Left panel,
green fluorescence from GFP-β2-chimaerin (wild-type or mutants); middle panels,
red fluorescence from pcDNA3.1/V5-p23/Tmp21; right panels, overlapped images.
Far right panels, co-localization images generated by Image J. Similar results were
obtained in 3 different experiments. Bar, 10 μm.

58

Identification of the chimaerin binding domain in p23/Tmp21
In the next set of experiments we mapped the domain in p23/Tmp21 that interacts
with the C1 domain in chimaerins using a yeast two-hybrid approach. p23/Tmp21
comprises a luminal domain and a short cytoplasmatic tail linked by a transmembrane
domain. Deletions for each domain were generated, and the corresponding deleted
mutants subcloned into pB42AD-HA as shown in Figure 2.12A (upper panel).
EGY48 (p8OP-LacZ) yeast was co-transformed with either mutant together with
pLexA-α-chimaerin (aa 1-147) (it has similar interacting properties as the βisoforms) and proteins expressed in Gal/Raf plates (Figure 2.12A, middle panel). A
strong interaction could be detected even when the cytosolic tail (Δ208-219) was
deleted. On the other hand, deletion of amino acids 185-208, which correspond to the
transmembrane domain, impaired the association. Expression of the transmembrane
domain alone was sufficient to observe interaction (Figure 2.12A, lower pannel). A
β-galactosidase liquid assay also revealed that the transmembrane domain alone
interacts with chimaerin (data not shown). These results were confirmed using a coprecipitation approach. Deletion mutants were generated and subcloned into pEBG
vector (Figure 2.12B, upper panel). GST or GST-fused p23/Tmp21 mutants were
mixed with COS-1 cell lysates expressing HA-β2-chimaerin (Figure 2.12B, middle
panel). While association of GST-p23/Tmp21 (aa 1-219; aa108-219; aa 1-208) with
HA-β2-chimaerin was readily detected, GST-p23/Tmp21 (aa 1-185), which has the
transmembrane domain deleted, failed to associate with β2-chimaerin (Figure 2.12B,
lower panel). These results suggest that p23/Tmp21 transmembrane domain is
implicated

in

the
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interaction.

Disruption of the β2-chimaerin-p23/Tmp21 complex leads to enhanced β2chimaerin Rac-GAP activity
We have previously shown that the expression levels of p23/Tmp21 may influence
the ability of β2-chimaerin to regulate Rac-GTP (active) levels (181). Conceivably,
when complexed with p23/Tmp21, β2-chimaerin cannot access the plasma membrane
to inactivate Rac. It is still elusive whether disruption of the β2-chimaerinp23/Tmp21 complex affects β2-chimaerin Rac-GAP activity. We predicted that
dissociation of this complex should result in enhanced availability of β2-chimaerin
for Rac inactivation. To address this issue, we compared the Rac-GAP activity of β2chimaerin (wild-type) and E227G/L248A-β2-chimaerin in COS-1 cells using a PBD
pull-down assay. As shown in Figure 2.13, the double mutant is more active as a RacGAP than wild-type-β2-chimaerin is when expressed at comparable levels. PMA
significantly enhanced Rac-GAP activity of wild-type β2-chimaerin. These results
suggest that binding of β2-chimaerin to p23/Tmp21 limits the availability of this RacGAP for inhibiting Rac activity.
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Figure 2.12 Identification of the β2-chimaerin C1 domain interacting region in
p23/Tmp21. EGY48 yeast (containing 8op-LacZ vector) was co-transformed with
pLexA-fused α1-chimaerin (aa 1-147) (181) and pB42AD-HA-tagged p23/Tmp21
truncated mutants. A. Upper panel, schematic representation of p23/Tmp21
constructs used in the yeast two-hybrid assay. Middle panel, chimaerin expression in
yeast lysates, as determined by Western blot using an anti-pLexA antibody; and
expression of p23/Tmp21 truncated proteins in yeast lysates using an anti-HA
antibody. Lower panel, assay of β-galactosidase activity on induction or no-induction
plates, carried out 72 h after transformation. Gal/Raf, galactosidase/raffinose. B.
COS-1 cells were transfected with either pEBG (empty vector) or pEBG-p23/Tmp21,
and infected with a HA-β2-chimaerin adenovirus (MOI=10 pfu/cell). Thirty-six h
later, GST or GST-p23/Tmp21 proteins were precipitated with glutathione Sepharose
4B beads and associated HA-β2-chimaerin detected by Western blot using an antiHA antibody. Upper panel, schematic representation of GST-p23/Tmp21 constructs
used in the co-precipitation assays. Middle panel, expression of GST-p23/Tmp21 or
its mutants and HA-β2-chimaerin in cell lysates. Lower panel, associated HA-β2chimaerin and GST-p23/Tmp21 or its mutants in pull-down assay were detected by
Western blot using anti-HA and anti-GST antibody respectively. Similar results were
observed in two additional experiments.

61

62

Figure 2.13 Disruption of β2-chimaerin-p23/Tmp21 interaction leads to enhanced
β2-chimaerin Rac-GAP activity. A. COS-1 cells were transfected with pEGFP,
pEGFP-β2-chimaerin (wt), or pEGFP-β2-chimaerin (E227G/L248A). Forty-eight h
later, Rac-GTP levels were assayed using a GST-PBD pull-down assay. B.
Densitometric analysis of Rac-GTP levels relative to control (GFP alone). Data are
expressed as mean ± S.E. of 5 independent experiments. *p<0.05 between GFP vs.
GFP-β2-chim (wt); **p<0.01 between GFP-β2-chim (wt) vs. GFP-β2-chim
(E227D/L248A). #p<0.01 between GFP-β2-chim (wt) (-PMA) vs. GFP-β2-chim(wt)
(+PMA). C. Western blot show GFP, GFP-β2-chim (wt) and GFP-β2-chim
(E227D/L248A) protein expression.
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Videos can be viewed at: http://www.molbiolcell.org/cgi/content/full/E09-080735/DC1
Figure 2.14 Videos for translocation experiments in Figure 2.9. Time-lapse images
of translocation of GFP-β2-chimaerin or its mutants in living cells were captured by
fluorescence microscopy at different time points after PMA treatment. AVI files
(movies) were made using Northern Eclipse software (version 6.0).
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DISCUSSION
In this Chapter we showed that p23/Tmp21 is an anchoring protein for the RacGAP β2-chimaerin and is required for its translocation to the perinuclear
compartment. The interaction is mediated through the β2-chimaerin C1 domain.
Interestingly, we found that C1 domains from other proteins, such as the second C1
domain of PKCε (C1εb), have the ability to interact with p23/Tmp21. However, a
comparative analysis between β2-chimaerin and PKCε suggests that p23/Tmp21
plays differential roles in targeting C1 domain-containing proteins, as only the former
interacts with p23/Tmp21 in response to phorbol ester activation. We also identified
key amino acids in the β2-chimaerin C1 domain required for the interaction that when
mutated prevent the formation of the complex.

C1 domains as targeting modules
It is well established that C1 domains play a fundamental role in targeting PKC
isozymes and other molecules from the cytosol to membranes both in response to
phorbol esters or DAG generated upon receptor activation (42). For classical and
novel PKCs, this membrane targeting is essential for allosteric activation. C1 domains
in other phorbol ester/DAG receptors also play key roles in translocation, as it has
been extensively demonstrated for PKDs, RasGRPs, and chimaerin Rac-GAPs. XRay crystallography studies of the C1b domain of PKCδ established that it is
constituted of two β sheets and a small α helix at the end of the C-terminus. The β
sheets form a pocket where phorbol esters and DAG bind (201). Modeling analysis
revealed that all C1 domains including those in chimaerins, have remarkable
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structural resemblance (26). The C1 domain in α- and β-chimaerins binds phorbol
esters and DAG analogs with affinities similar to PKC C1 domains and utilizes
similar mechanisms for insertion into lipid bilayers (26). It is remarkable, however,
that individual C1 domains from phorbol ester/DAG receptors have quite distinct
properties for ligand recognition and localize to entirely different compartments when
expressed in cells. Various examples of differential ligand affinities have been
reported for C1a and C1b domains in PKC isozymes. For example, a study showed
that while in PKCδ the C1a domain preferentially binds DAG, the C1b domain has
higher affinity for phorbol esters (166). Site-directed mutagenesis of individual C1
domains in PKCs has also established distinct roles in translocation, and it was
suggested that this disparity relates to a differential exposure of C1a and C1b domains
(148). The non-equivalency of C1 domains in PKCs is also exemplified by their
differential ability to localize to the Golgi complex: while isolated C1a domains
generally localize throughout the cell rather than specifically in the perinuclear
region, C1b domains of cPKCs and nPKCs show co-localization with a Golgi marker
(153), as we have also demonstrated for full-length β2-chimaerin and its isolated C1
domain (27), and brefeldin can disrupt their localization (111). In PKDs, a family of
PKC-related kinases, C1a and C1b domains also have differential biochemical and
targeting properties (36, 109). Altogether, this suggests that mechanisms alternative
or in addition to ligand binding may account for the selective intracellular
compartmentalization.
Growing evidence suggests that C1 domains in PKCs and PKDs act as proteininteraction modules that regulate their cellular localization and/or activation. For
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example, the C1b domain of PKCα interacts with the cell matrix protein fascin, and
disruption of this interaction affects cell motility (4). 14-3-3τ binding sites have been
identified within the C1b domain of PKCγ (135). The association between the PKD1
C1 domain and 14-3-3τ in T cells negatively regulates PKD1 (78). The recent
identification of a 20 amino acid module in PKCε that directs localization to cell-cell
contacts via protein-protein interaction is another remarkable example (51). The
PKCε C1b binds to peripherin to induce its aggregation, leading to apoptosis in
neuroblastoma cells (169). Localization of PKCβII to centrosomes is mediated by the
scaffolding protein pericentrin and involves the PKCβII C1a domain, and dissociation
of this complex impairs spindle formation and cell division (34). Newton and coworkers identified a novel E3 ubiquitin ligase that interacts with the C1a domain of
PKCβII (33).
The identification of p23/Tmp21 as a β2-chimaerin interactor allowed us to
postulate an anchoring role for this Golgi protein. In this study we showed that RNAi
depletion of p23/Tmp21 prevents the translocation of β2-chimaerin to the perinuclear
region, an indication that binding to p23/Tmp21 is a requisite for relocalization.
Deletion of the C1 domain in β2-chimaerin prevents β2-chimaerin interaction with
p23/Tmp21 (181), and this is also supported by the failure of the C1 domain mutant
C246A-β2-chimaerin to associate with p23/Tmp21 observed in the present study. We
also investigated the role of two highly conserved amino acids in the C1b domains of
PKCs. Previous studies by Schultz et al. showed that Asp257 and Met278 in PKCε
(positions 15 and 36 in the C1 domain consensus) or the equivalent residues in PKCθ
(Glu246 and Met267) are required for Golgi targeting (153). Like PKC C1b domains,
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the C1 domain in β2-chimaerin possesses an acidic residue in position 15 (Glu227)
and a hydrophobic residue in position 36 (Leu248). We found that mutation of both
residues abolishes perinuclear translocation of β2-chimaerin. It is unclear why single
mutants were not as effective, but Shultz et al. also described similar results for single
mutants in PKCθ (153). It is interesting that, unlike β2-chimaerin, PKCε loses its
perinuclear localization in response to PMA and mobilize to a peripheral
compartment. Most likely the forces that drive membrane translocation are
sufficiently strong to overcome the PKCε-p23/Tmp21 interaction. The C1a domain in
PKCε may suffice to drive plasma membrane localization, as the tandem C1a-C1b
domain mobilizes to the plasma membrane in response to PMA (data not shown). In
addition to its perinuclear relocalization, β2-chimaerin translocates to the plasma
membrane in response to stimuli (184). It remains to be determined whether signals
could lead to the dissociation of the complex and release β2-chimaerin to make it
available for membrane translocation or whether different intracellular pools that
respond differentially to stimuli exist. The ability of chimaerins to interact with other
proteins independently of the C1 domain (Colon-Gonzalez, H.W., and M.G.K.,
manuscript in preparation) clearly suggests complex regulatory mechanisms
controlling relocalization and activation of this family of Rac-GAPs.
A key finding was the identification of amino acids 15 and 36 in the C1 domain
consensus as essential for the interaction with p23/Tmp21. Mutation of both residues
in β2-chimaerin impairs the interaction with p23/Tmp21 in a yeast two-hybrid assay.
Likewise, mutation of amino acids Asp257 and Met258 in PKCε leads to dissociation
of this kinase from the perinuclear compartment (see Figure 2.8). The differential
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interaction of PKCε C1a and C1b domains with p23/Tmp21 may also reflect the
differences in amino acids present in those positions (Ser and Cys in C1a). While at
the present time there is no structural information on the C1 domain-p23/Tmp21
interaction, 3D studies clearly showed that amino acids in position 15 and 36 are in
close proximity and possibly not inserted into the membrane bilayer (153, 201), thus
making them available for interactions with other partners.

p23/Tmp21 as an anchoring protein for β2-chimaerin
p23/Tmp21 is a type I protein belonging to the p24 family that has a receptor-like
luminal domain and a short cytoplasmatic tail. Members of the p24 family have been
widely implicated as coat protein (COP) vesicle cargo receptors, and they participate
in COP vesicle budding and the organization of the Golgi apparatus. The cytoplasmic
tail of p23/Tmp21 carries motifs that bind to COPI, and this association is crucial for
the retention and retrieval of cargo proteins in the early secretory pathway (65). Our
deletional analysis revealed that this C-terminal tail is not involved in binding to
chimaerins. Despite multiple studies implicating p24 proteins in vesicle trafficking,
insights into the actual function of p23/Tmp21 remain elusive. Recent studies have
established that p23/Tmp21 is a component of the presenilin complex that modulates
γ-secretase activity (35). p23/Tmp21 can also localize in post-Golgi compartments
and even traffic to the plasma membrane (17). In addition, emerging evidence
suggests that p23/Tmp21 is implicated in the regulation of small GTPase function.
Studies identified a mechanism of recruitment of the small GTPase ARF1 (ADPribosylation factor 1) to the Golgi via p23/Tmp21 (65, 112). More recently, studies
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found that ARF1-dependent assembly of actin in the Golgi apparatus may involve
Cdc42/Rac and is dependent on p23/Tmp21 (57). While early studies showed that
Rac1 is present in the perinuclear region, primarily in an inactive GDP-bound state
(95), functional studies on perinuclear Rac are scarce. Moreover, it is unclear what
the relative contribution of this perinuclear-associated Rac is to the pool of active
plasma membrane Rac generated in response to stimuli. It may be possible that
recruitment of chimaerin Rac-GAPs via p23/Tmp21 contributes to the maintenance of
the perinuclear Rac inactive pool. There is a precedent for the interaction of
endogenous Rac and a Rac-GAP protein, OCRL1, at the trans-Golgi network,
however the mechanisms involved in targeting these proteins to the perinuclear
region are yet to be established.

Conclusion of Chapter 2
We identified p23/Tmp21 as an anchoring protein for β2-chimaerin via its C1
domain. Depletion of p23/Tmp21 from cells leads to reduced perinuclear
translocation of β2-chimaerin, suggesting that when complexed with p23/Tmp21 its
availability to mobilize to the plasma membrane and inactivate Rac is limited. Our
studies also provide evidence for a marked selectivity of C1 domains for binding to
p23/Tmp21, as some C1 domains from PKC isozymes and potentially other phorbol
ester/DAG receptors have the ability to bind p23/Tmp21. In the case of PKCε it
seems that p23/Tmp21 anchors this kinase via the C1b domain and that the PKCεTmp21 complex dissociates in response to stimuli. Whether this is also true for other
PKC isozymes or phorbol ester/DAG receptors such as PKD and RasGRP isozymes
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remains to be determined. In summary, the ability of C1 domains to dictate
intracellular localization via protein-protein interactions expands our view that these
domains act solely as lipid-binding motifs and highlight the complexity of DAG
signaling.
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MATERIALS AND METHODS

Materials- PMA and GF109203X were purchased from LC Laboratories (Woburn,
MA). Cell culture reagents were obtained from Invitrogen (Carlsbad, CA). Reagents
for the expression and purification of recombinant glutathione S-transferase (GST)fusion proteins and glutathione Sepharose 4B beads were purchased from GE
Healthcare (Piscataway, NJ). COS-1 and HeLa cells were obtained from the
American Type Culture Collection (ATCC, Manassas, VA). Yeast strain EGY48, and
yeast culture reagents and media were obtained from Clontech Laboratories, Inc.
(Mountain

View,

CA).

ONPG

(O-nitrophenyl-β-D-galactopyranoside)

and

MISSION® Lentiviral Transduction shRNAs particles were obtained from Sigma (St.
Louis, MO). The following primary antibodies were used: anti-pLexA (Santa Cruz,
CA),

anti-β-actin

(Sigma),

anti-V5

(Invitrogen),

anti-p23/Tmp21

(ProSci

Incorporated, Poway, CA), anti-GST, anti-HA and anti-GFP (Covance, Emeryville,
CA), anti-Rac1 (Millipore, Billerica, MA), anti-PKCε (Cell Signaling, Danvers, MA),
and anti-GS28 (BD Biosciences, San Jose, CA).

Plasmid construction- Generation of pB42AD-p23/Tmp21 (amino acid (aa) 108-219),
pEBG-p23/Tmp21 (aa 1-219) and pEBG-p23/Tmp21 (aa 108-219) are described
elsewhere (181). Truncated p23/Tmp21 mutants were generated by PCR and
subcloned into EcoRI-XhoI sites in pB42AD-HA vector or BamHI /SpeI sites in
pEBG vector. C1 regions from PKCε, PKCζ and β2-chimaerin were isolated by PCR
and fragments subcloned into EcoRI-BamHI sites in pLexA to generate pLexA-C1εa-
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b (aa 134-309), pLexA-C1ζ (aa 95-197), and pLexA-C1β2-ch (aa 179-281),
respectively. C1 domain fragments were also subcloned into EcoRI-BamHI sites in
pEGFP-C1 to generate pEGFP-C1εa-b, pEGFP-C1ζ, and pEGFP-C1β2-ch.
Individual C1a and C1b domains from PKCε (comprising aa 168-222 and aa 241294, respectively) were subcloned into EcoRI-BamHI sites in pEGFP-C1 and pLexA
to generate pEGFP-C1εa, pEGFP-C1εb, pLexA-C1εa, and pLexA-C1εb. The primers
used for PCR cloning are listed in Table 2-1. All constructs were confirmed by
sequencing.

Site-directed mutagenesis- For PCR-based mutagenesis we employed the
QuikChange® XL Site-Directed Mutagenesis Kit (Strategene, La Jolla, CA), using
GFP-β2-chimaerin, GFP-C1β2-ch, or pLexA-C1β2-ch as templates. For the mutant
E227G-β2-chimaerin we used the following primers (mutated nucleotides are
underlined):

forward,

5’-

CGAGGCCCACACTGGTGTGGATATTGTGCCAATTTCATG;

reverse,

5’-

CATGAAATTGGCACAATATCCACACCAGTGTGGGCCTCG. For the mutant
L248A-β2-chimaerin

we

used:

forward,

GTCCGGTGCTCAGACTGTGGAGCTAACGTACACAAACAG;

reverse,

CTGTTTGTGTACGTTAGCTCCACAGTCTGAGCACCGGAC.

For

(E257G)

we

used:

GGTCCCCACGTTCTGTGGCCACTGTGGGTCCCTGC;

forward,
reverse,

5’–
5’PKCε
5’5’-

GCAGGGACCCACAGTGGCCACAGAACGTGGGGACC. For PKCε (M278G) we
used:

forward,
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5’-

GCAGTGTAAAGTCTGCAAAGGGAATGTTCACCGTCGATGTG; reverse, 5’CACATCGACGGTGAACATTCCCTTTGCAGACTTTACACTGC.

Cell culture, transfections, and adenoviral infections- HeLa and COS-1 cells were
cultured in Dulbecco's modified Eagle's medium (Invitrogen) supplemented with 10%
fetal bovine serum (Cyclone), 100 units/ml penicillin, and 100 µg/ml streptomycin in
a humidified 5% CO2 atmosphere at 37 °C. Cells in 6-well plates at ~50% confluence
were transfected with different mammalian expression vectors (1 µg) using
Lipofectamine 2000 (Invitrogen) following the manufacturer's protocol. Adenoviral
infections were carried out essentially as previously described (101).

Generation of p23/Tmp21-depleted cell lines using shRNA lentiviruses- HeLa cells
were infected with 3 different MISSION® Lentiviral Transduction particles encoding
p23/Tmp21 shRNAs. p23/Tmp21 shRNA target sequences were as follows: #1,
CCGGGAGATTCACAAGGACCTGCTACTCGAGTAGCAGGTCCTTGTGAATC
TCTTTTT;

#2,

CCGGCCAACTCGTGATCCTAGACATCTCGAGATGTCTAGGATCACGAGTT
GGTTTTT.

#3,

CCGGCGCTTCTTCAAGGCCAAGAAACTCGAGTTTCTTGGCCTTGAAGAAG
CGTTTTT; Stable cell lines (pools) were generated by selection with puromycin (1
μg/ml).
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Yeast two-hybrid assay- pLexA expression vectors, which contain a His marker, were
co-transformed into the yeast strain EGY48 together with pB42AD-HA-tagged
expression vectors, which have a Trp marker, and the p8OP-LacZ reporter vector
(Ura marker). Transformants were plated on yeast dropout medium lacking Trp, Ura,
and His, thereby selecting for the plasmids encoding proteins capable of two-hybrid
interaction as evidenced by transactivation of the LacZ reporter gene (181).
For β-galactosidase liquid assays, yeast was cultured in galactose/raffinose/-His/Ura/-Trp liquid SD selection medium until the cells were in mid-log phase (OD600 =
0.5-0.8). Cells were pelleted at 14,000 x g for 30 sec, and resuspended in 300 μl of a
buffer (pH 7.0) containing 60 mM Na2HPO4, 40 mM NaH2PO4.H2O, 10 mM KCl, 1
mM MgSO4, and 0.27% (v/v) β-mercaptoethanol. One hundred μl of the cell
suspension were then frozen and thawed 3 times in liquid nitrogen and a 37oC water
bath, respectively, and additional 700 μl of resuspension buffer were added. ONPG
was then added (final concentration: 670 μg/ml), and the reaction initiated by addition
of Na2CO3 (final concentration: 300 μg/ml). β-galactosidase activity was determined
as previously determined (181). One unit of β-galactosidase activity is defined as the
amount that hydrolyzes 1 μmol of ONPG to o-nitrophenol and D-galactose per min
and per cell.

Immunostaining and confocal microscopy- Plasmids encoding for full-length PKCε
or β2-chimaerin together with p23/Tmp21 in V5 epitope-tagged pcDNA3.1 were cotransfected into HeLa cells using Lipofectamine 2000. After 24 h, cells were treated
with PMA for 30 min, washed twice with PBS, and fixed with 4% paraformaldehyde
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for 20 min at room temperature. After washing once with PBS containing 0.5% SDS
and 5% β-mercaptoethanol (37°C, 30 min), and twice with PBS alone, cells were
incubated with an anti-V5 monoclonal antibody (1:500). A donkey anti-mouse
antibody conjugated with Cy3 was used as secondary antibody (1:1,000). Slides were
mounted using Fluoromount-G (SouthernBiotech, Birmingham, AL) and viewed with
a Carl Zeiss LSM 710 laser scanning microscope. The confocal images were
processed with LSM Image Browser. All the images shown are individual middle
sections of projected Z-series mounting. For quantification, images (RGB) from Red
and Green channels were converted into 8-bits images in ImageJ and the Pearson’s
correlation coefficient (Rr) calculated using this software.

Time-lapse microscopy- HeLa cells were seeded into glass-bottomed culture dishes
(MatTek, Ashland, MA) for 20 h. pEGFP-PKCε or pEGFP-β2-chimaerin plasmids
(wild-type or mutants) were transfected using Lipofectamine 2000 according to the
manufacturer’s protocols. Cells were cultured for 20 h in Phenol red-free RPMI-1640
medium containing 10% FBS and 5 mM HEPES. Cells were monitored under a
fluorescence microscope (Nikon Eclipse TE2000U) at a 488 nm excitation
wavelength with a 515 nm-long pass barrier filter at 25oC.

Co-precipitation using glutathione Sepharose 4B beads- COS-1 cells at ~50%
confluency were co-transfected with pEBG-p23/Tmp21 (full-length) or empty vector
(pEBG). After 24 h, cells were washed twice with cold PBS, and then lysed for
10 min at 4°C in 400 µl of a lysis buffer containing 50 mM Tris-HCl, pH
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7.5, 150 mM NaCl, 1% Nonidet P-40, 0.5% deoxycholate, 0.1% SDS, and protease
inhibitor cocktail (Sigma). Ten µl of glutathione Sepharose 4B beads were added to
the lysate and incubated for 1 h at 4°C. The beads were extensively washed in lysis
buffer and boiled. Samples were resolved in a 12% SDS-polyacrylamide gel and
transferred to a polyvinylidene difluoride membrane (Millipore Co., Bedford, MA)
for Western blot analysis.

In vitro protein-protein binding assay- Cell lysates were prepared from COS-1 cells
expressing pEBG, pEBG-p23/Tmp21 (aa 1-219), pEBG-p23/Tmp21 (aa 1-208),
pEBG-p23/Tmp21 (aa 108-219) or pEBG-p23/Tmp21 (aa 1-185). A fixed amount of
GST or GST-fused p23/Tmp21 (wild-type or truncated mutants) were incubated with
lysates of COS-1 cells expressing HA-β2-chimaerin at 4oC for 2h, and then incubated
with glutathione Sepharose 4B beads for 1 h. After extensive washing, the beads were
boiled in loading buffer and subjected to Western blot with an anti-HA antibody.

Determination of Rac-GTP levels- Experiments were carried out as previously
described (181). Briefly, cells were lysed in a buffer containing 8 µg of GST-PBD
(p21-binding domain), 20 mM Tris-HCl, pH 7.5, 1 mM dithiothreitol, 5 mM MgCl2,
150 mM NaCl, 0.5% Nonidet P-40, 5 mM β-glycerophosphate, and protease
inhibitors cocktail (Sigma). Lysates were centrifuged at 14,000 × g (4°C, 10 min) and
then incubated with glutathione Sepharose 4B beads (4°C, 1 h). After extensive
washing, the beads were boiled in loading buffer and subject to Western blot analysis
using an anti-Rac1 antibody.
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Western blot- Non-specific binding in membranes was blocked by incubation with 5%
nonfat milk or 5% bovine serum albumin for 2 h. Membranes were then incubated
with primary antibodies for 2 h at room temperature, followed by incubation with
peroxidase-conjugated goat anti-mouse or anti-rabbit IgG (1:3,000 or 1:10,000) for 1
h at room temperature. Immunoreactivity was visualized with a FUJIFILM LAS3000
image reader using an enhanced chemoluminescence detection kit (Amersham).
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Table 2.1 Primers used to generate constructs
Constructs
pB42AD-Tmp21 (aa 108-208):
Forward:
Reverse:
pB42ADTmp21 (aa108-185):
Forward:
Reverse:
pB42ADTmp21 (aa183-211):

Primers
ccggaattctgttttgagagcaagggaacaggg
ccgctcgagcaggtagaagacctgccag
ccggaattctgttttgagagcaagggaacaggg
ccgctcgagccgagtgtttgttgactcgttgg

Forward:ggaattcgtcctatacttcagcatcttttcaatgttctgtctcattggactagctacctg
gcaggtcttctacctgctcgagcgg
Reverse:ccttaagcaggatatgaagtcgtagaaaagttacaagacagagtaacctgatcgatggac
cgtccagaagatggacgagctcgcc
pEBG-p23/Tmp21 (aa 1-219)
Forward:
ccgctcgaggatccatgtctggtttgtctggccc
Reverse:
gactagtctactcaatcaatttcttggcc
pEBG-p23/Tmp21 (aa 108-219)
Forward:
gaagatctctcgaggatccatgtgttttgagagcaaggg
Reverse:
gactagtctactcaatcaatttcttggcc
pEBG-p23/Tmp21 (aa 1-208)
Forward:
ccgctcgaggatccatgtctggtttgtctggccc
Reverse:
gactagtctagcgtcgcaggtagaagacc
pEBG-p23/Tmp21 (aa 1-185)
Forward:
ccgctcgaggatccatgtctggtttgtctggccc
Reverse:
gactagtctaccgagtgtttgttgactcg
PKCαC1a-b
Forward
ccggaattcatggctgacgttttcccgggcaacga
Reverse
cgcggatccctaaacctcagcctttaggtaaatcc
PKCε C1a-b
Forward
ccggaattctcgtcgggtgaagcccctaaagacaatg
Reverse
cgcggatccctaggtaacgcccaggtcggccagtactttg
PKCδ C1a-b
Forward
ccggaattcgaggacgtggattgcaaacagtctatg
Reverse
cgcggatccctatctctgggtgacttggttcaaggcct
PKCζ C1
Forward
ccggaattcgttttcccgagcacccctgagcagcctg
Reverse
cgcggatccctaagactctgccccagggctaagcaaatc
RasGRP1 C1
Forward
Reverse
β2-chimaerin C1
Forward
Reverse
PKCε C1a
Forward
Reverse
PKCε C1b
Forward
Reverse

ccggaattcttctgtgtgatggacaaagatagg
cgcggatcccacagagctgatgttttctgtgg
ccggaattcaaaacaaacgtcacacatgaagaacacacagc
cgcggatccctatgttgtgaggtcacaacagtacact
gaattcaacggccacaagttcatg
ggatcccccagcacactttgtgatta
gaattcatgccccacaagttcggtat
ggatcccactccacagttgggag
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CHAPTER 3
p23/Tmp21, an ER/Golgi cargo protein, regulates phorbol esterinduced apoptosis in LNCaP prostate cancer cells via direct
association with PKCδ
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ABSTRACT
It has been established that androgen-dependent prostate cancer cells undergo
apoptosis in response to phorbol esters treatment, and that this effect was primarily
mediated by nPKCδ. In the present chapter we demonstrate that depletion of
p23/Tmp21 significantly potentiates PMA-induced apoptosis in LNCaP cells. The
effect was rescued by PKCδ RNAi depletion or the pan-PKC inhibitor GF 109203X,
suggesting that the enhancing apoptotic effect of p23/Tmp21 depletion was mediated
by PKCδ. Yeast two-hybrid assay revealed that the PKCδ C1a-b domain interacts
with p23/Tmp21. In addition, co-localization analysis by confocal microscopy
demonstrated that GFP-PKCδ C1b domain co-localizes with p23/Tmp21 in the
perinuclear region. More importantly, the authenticity of the interaction between
PKCδ and p23/Tmp21 was confirmed by showing that endogenous PKCδ coimmunoprecipitated and co-localized with endogenous p23/Tmp21 in LNCaP cells.
Interestingly, disruption of PKCδ-p23/Tmp21 association by depletion of p23/Tmp21
significantly accelerated PMA-induced PKCδ translocation to the plasma membrane
and activated PKCδ downstream effectors. Furthermore, our experiments also
demonstrated that depletion of p23/Tmp21 potentiates apoptosis induced by the DNA
damage agent doxorubicin. In summary, our data provide evidence that PKCδ
associates with p23/Tmp21, and suggest that p23/Tmp21 acts as an anchoring protein
that retains PKCδ at the perinuclear region, thus limiting its availability for signaling.
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INTRODUCTION
As described in Chapter 2, we identified p23/Tmp21 as a binding protein for
chimaerin Rac-GAPs and showed that p23/Tmp21 negatively regulates the Rac-GAP
activity of β2-chimaerin. Mutation or deletional analysis demonstrated that the
interaction is mediated by the C1 domain in chimaerins (181). We also showed in
Chapter 2 that p23/Tmp21 associates with the PKCε C1b domain. Interestingly, a
yeast two-hybrid assay also revealed that p23/Tmp21 could interact with C1 domains
from other phorbol ester/DAG receptors, including RasGRP1, PKCα, and
PKCδ (183). The functional relevance of the C1 domain-p23/Tmp21 association has
not been thoroughly elucidated in the context of PKC-mediated responses.
PKCδ is an important pro-apoptotic kinase in androgen-dependent prostate cancer
cells (58, 66, 147, 174, 193, 198). Activation of PKCδ by PMA induces apoptosis in
LNCaP cells (58). The signaling events downstream of PKCδ include the activation
of the small GTPase RhoA and its target ROCK (193), activation of JNK and p38
MAPK (174), and dephosphorylation of Akt (174). It has been reported that PKCδ
activity is also required for the apoptotic effect of DNA damage agents such as
etoposide and doxorubicin in cancer cells (49, 143). A yeast two-hybrid assay
demonstrated that p23/Tmp21 can interact with the PKCδ C1a-b domain. We propose
that p23/Tmp21 may regulate PKCδ-mediated apoptosis through their interaction.
In the present chapter we investigate the functional relevance of the PKCδp23/Tmp21 association in LNCaP prostate cancer cells. A remarkable finding is that
the association between p23/Tmp21 and PKCδ modulates apoptosis in LNCaP
prostate cancer cells induced by PMA and doxorubicin. p23/Tmp21 possibly anchors
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PKCδ in the ER/Golgi compartment and in this manner limits the ability of PKCδ to
translocate to the plasma membrane. Our study also revealed a novel function for
p23/Tmp21 in regulating apoptotic cell death in addition to its well-established role in
vesicle formation and cargo trafficking.
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RESULTS
p23/Tmp21 directly interacts with PKCδ in LNCaP prostate cancer cells
Our studies have demonstrated that p23/Tmp21 interacts with α-, β- chimaerin,
and PKCε through their C1 domains (181, 183). We speculated that there is a direct
interaction between p23/Tmp21 and PKCδ through the same region. We first
addressed this issue by using a yeast two-hybrid approach. pLexA constructs
encoding C1δa-b, C1ζ or C1β2-chim were generated (Figure 3.1A, upper panel) and
co-transformed with pB42AD-p23/Tmp21 (HA-tagged, aa 108-208, a fragment that
interacts with C1 domain of chimaerins) into EGY48 yeast containing p8OP-LacZ
vector (181, 183). The triple vector co-transformants were selected by plating the
yeast into SD/-Ura/-His/-Trp dropout plates. pLexA-fused proteins were expressed in
both galactose/raffinose (+Gal/Raf) plates and glucose plates (-Gal/Raf), while HAtagged pB42AD-p23/Tmp21 (aa 108-208) was only expressed in galactose/raffinose
induction plates (Figure 3.1A, lower panel). Figure 3.1A (middle panel) shows that
the C1δa-b and C1β2-chim (positive control) interacted with p23/Tmp21, as revealed
by the induction of the LacZ reporter (blue color). In agreement with our previous
results, C1ζ (negative control) did not interact with p23/Tmp21. These interactions
were also detected using a liquid β-galactosidase assay (data not shown).
To confirm the interaction between p23/Tmp21 and PKCδ at the cellular level, we
first used a co-precipitation approach. COS-1 cells were transfected with pEBG
vector (encoding GST protein) or pEBG-p23/Tmp21 (encoding GST-p23/Tmp21).
Twenty-four h later, cells were infected with PKCδ adenovirus (3 MOI) and cultured
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for 24 h. As shown in Figure 3.1B, no association was detected with GST alone,
whereas significant PKCδ was detected in association with GST-p23/Tmp21.
In the next experiment we assessed the localization of various PKCδ-deleted
mutants. HeLa cells were transfected with pEGFP-fused PKCδ (full-length),
PKCδ C1a-b, PKCδ C1a, or PKCδ C1b. As shown in Figure 3.2B, PKCδ C1a and
C1b domains differentially localize in cells. While PKCδ C1b domain mainly
localized in the perinuclear region, the PKCδ C1a domain evenly distributes in the
cells without any significant perinuclear localization. In that regard, these results
resembled those observed for PKCε (see Chapter 2). To demonstrate co-localization
of PKCδ and p23/Tmp21, HeLa cells were co-transfected with the different pEGFPPKCδ plasmids together with pcDNA3-V5-p23/Tmp21, a plasmid encoding V5tagged p23/Tmp21, and co-localization was determined by confocal microscopy. We
observed that PKCδ full-length and the PKCδ C1b domain co-localized with
p23/Tmp21 in the perinuclear region, as judged by the yellow color observed in the
overlapped images (Figure 3.2C).
As PKCδ plays a critical role in PMA-induced apoptosis in LNCaP cells, we next
decided to use this paradigm to examine any potential modulation by p23/Tmp21. We
speculated that the association between PKCδ and p23/Tmp21 regulates PKCδmediated apoptosis in LNCaP cells. First, we performed co-immunoprecipitation
experiments to examine the association of endogenous PKCδ and p23/Tmp21 in
LNCaP cells. In this experiment we used an anti-PKCδ antibody to pull-down
endogenous PKCδ, and examined if p23/Tmp21 co-precipitates with PKCδ. As
shown in Figure 3.3A, the interaction between PKCδ and p23/Tmp21 could be
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readily detected in LNCaP cells. We then examined co-localization of PKCδ and
p23/Tmp21 in LNCaP cells by confocal microscopy. LNCaP cells expressing GFPPKCδ were immunostained for endogenous p23/Tmp21. As shown in Figure 3.3 B,
GFP-PKCδ co-localized with p23/Tmp21 in the perinuclear region as judged by the
yellow color in the overlapped images. Furthermore, by using immunostaing analysis
we found that endogenous PKCδ and p23/Tmp21 co-localized in LNCaP cells
(Figure 3.3C). Collectively, these results confirmed that PKCδ interacts with
p23/Tmp21 in LNCaP prostate cancer cells.
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Figure 3. 1 A. Yeast two-hybrid assay reveals that the PKCδ C1a-b domain interacts
with p23/Tmp21. Schematic representation of C1δa-b, C1ζ, or C1β2-ch domain fused
to pLexA (upper panel). EGY48 yeast (containing 8op-LacZ vector) was cotransformed with pLexA encoding C1δ a-b, C1ζ, or C1β2-ch domain, and pB42ADHA-tagged p23/Tmp21 (aa 108-208). Assay of β-galactosidase activity on induction
(+GF) or no-induction (-GF) plates was carried out 72 h after transformation. GF,
galactosidase/raffinose (middle panel). Expression of pLexA fused C1δa-b, C1ζ and
C1β2-chim using an anti-pLexA antibody and expression of pB42AD-HAp23/Tmp21 (aa 108-208) using an anti-HA antibody (lower panel). B. PKCδ forms a
complex with p23/Tmp21 in COS-1 cells. COS-1 cells were transfected with either
pEBG (empty vector) or pEBG-p23/Tmp21. Twenty-four h later, cells were infected
with PKCδ adenovirus (MOI=3 pfu/cell). After twenty-four h, GST or GSTp23/Tmp21 proteins were precipitated with glutathione Sepharose 4B beads and
associated PKCδ detected by western blot using an anti-PKCδ antibody. Upper panel,
representative experiment. Lower panel, densitometric analysis of three individual
experiments, expressed as fold-change relative to GST.
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Figure 3.2 The C1b domain of PKCδ mediates perinuclear targeting and co-localizes with
p23/Tmp21. A. Schematic representation of C1δa-b , C1δa, C1δb, or full-length PKCδ fused
to GFP. B. C1δb localizes in the perinuclear region. HeLa cells were transfected with
pEGFP-fused PKCδ, C1δa-b, C1δa, or C1δb. Forty-eight h later, cells were treated with
PMA (1 μM, 30 min) or vehicle, fixed, and localization examined by confocal microscopy.
C. HeLa cells were co-transfected with pEGFP-PKCδ plasmids together with pcDNA3.1-V5p23/Tmp21. Forty-eight h later, cells were fixed and co-localization examined by confocal
microscopy. Similar results were observed in three independent experiments.
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Figure 3.3 PKCδ and p23/Tmp21 form a complex in LNCaP prostate cancer cells. A.
LNCaP cells were lysed. Cell lysates were centrifuged at 14, 000× g for 10 min and
the supernatant precleared with 15 μl of protein A agarose beads (invitrogen) for 1 h
at 4°C. After a short centrifugation, the supernatant was used for immunoprecipitation
with an anti-PKCδ antibody or control IgG (4°C, 2 h). Representative western blots
of the supernatant and the immunoprecipitation are shown. B. pEGFP-PKCδ colocalizes with p23/Tmp21 in LNCaP prostate cancer cells. GFP-PKCδ was
transfected into LNCaP cells using the Amaxa Nucleofector following the
instructions provided by the manufacturer. Forty-eight h later, cells were fixed and
p23/Tmp21 was stained with and anti-p23/Tmp21 primary antibody followed by a
Cy3-conjugated secondary antibody. Co-localization was examined by confocal
microscopy. C. Co-localization of endogenous PKCδ and p23/Tmp21. All
experiments have been performed three times with similar results.
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p23/Tmp21 modulates apoptotic responses in LNCaP cells
To determine the role of p23/Tmp21 in PMA-induced apoptosis in LNCaP cells,
we depleted p23/Tmp21 from LNCaP cells using a p23/Tmp21 specific RNAi duplex,
and then treated cells with PMA to assess the apoptotic response. Remarkably,
depletion of p23/Tmp21 significantly potentiated PMA-induced apoptosis of LNCaP
cells (Figure 3.4A). To further confirm this effect, we used p23/Tmp21 knockdown
stable cell lines (see Chapter 2). In agreement with results in transiently depleted
cells, stable depletion of p23/Tmp21 also resulted in a higher PMA-induced apoptotic
response relative to control cells (Figure 3.4B). Our results suggest that p23/Tmp21
plays a negative role in regulating PMA-induced apoptosis. In addition, we found that
depletion of p23/Tmp21 by RNAi also enhanced the apoptotic effect of the DNA
damage doxorubicin in LNCaP cells (Figure 3.4C). Interestingly, several reports
showed PKCδ mediates the death effect of DNA damaging agents in prostate cancer
cells (15).

p23/Tmp21 regulates PMA-induced apoptosis through PKCδ
Previous studies have demonstrated that PKCδ played a central role in PMAinduced apoptosis of LNCaP cells. Inhibition or RNAi depletion of PKCδ abolishes
PMA-induced apoptosis in LNCaP cells (66). To determine if the potentiating effect
of p23/Tmp21 depletion on PMA-induced apoptosis is mediated through PKCδ, we
examined if PKCδ depletion could prevent this effect. As shown in Figure 3.5B,
PKCδ/p23/Tmp21 double knockdown cells had significantly decreased apoptosis,
suggesting that the potentiating effect of p23/Tmp21 depletion on PMA-mediated.
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Figure 3.4 Depletion of p23/Tmp21 potentiates PMA- and doxorubicin-induced apoptosis in
LNCaP prostate cancer cells. A. LNCaP cells were transiently transfected with p23/Tmp21
or control (CTL) RNAi duplexes. After 48 h, cells were treated with vehicle or PMA and the
incidence of apoptosis determined 24 h later. B. LNCaP cells stably expressing different
p23/Tmp21 shRNAs (shRNA#1, or shRNA#2) or control shRNA were treated with vehicle or
PMA, and the incidence of apoptosis determined 24 h later. C. LNCaP cells were transiently
transfected with p23/Tmp21, PKCδ or control (CTL) RNAi duplexes. After 48 h, cells were
treated with vehicle or doxorubicin (1 μg/ml for 2 h) and the incidence of apoptosis
determined 24 h later. D. Western blot for the expression of p23/Tmp21 in LNCaP cells
transiently depleted of p23/Tmp21 (upper panel) and LNCaP stable cell lines expressing
p23/Tmp21 shRNA (lower panel).
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apoptosis in LNCaP cells is mediated through PKCδ. As a second approch, we
analyzed the effect of GF 109203X, a pan-PKC inhibitor. As shown in Figure 3.5C,
GF 109203X essentially abolished apoptosis in response to PMA treatment both in
control and p23/Tmp21 knockdown cells. These results suggest that p23/Tmp21
depletion potentiates PMA-induced apoptosis through enhanced PKCδ activation.

Depletion of p23/Tmp21 facilitates PKCδ translocation to the plasma membrane
To establish if depletion of p23/Tmp21 affects PKCδ activation in LNCaP cells,
we first examined PMA-induced translocation of GFP-PKCδ. LNCaP cells were
treated with 30 nM PMA, a concentration at which translocation of PKCδ is not
readily detected by microscopy in LNCaP cells. Interestingly, significant plasma
membrane translocation of GFP-PKCδ could be observed at about 5-10 min in
p23/Tmp21-depleted LNCaP cells under this experimental condition (Figure 3.6B).
These results demonstrated that depletion of p23/Tmp21 facilitates PMA-induced
PKCδ plasma membrane translocation and therefore its activation.
Our laboratory recently reported that ROCK and JNK are downstream effectors of
PKCδ that mediate the apoptotic effect of PMA in LNCaP prostate cancer cells (193).
PMA at 100 nM caused significant activation of JNK, as assessed with an antiphospho-JNK antibody. PMA treatment also activates Rho and ROCK, and it induces
the phosphorylation of the ROCK effector MYPT-1 in Thr850. Notably, we found a
significant potentiation of JNK and MYPT- phosphorylation in response to PMA in
p23/Tmp21 knockown LNCaP cells compared to control cells. Figure 3.7 shows a
representative experiment using 30 nM PMA, a concentration that causes only a
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partial response and allows better detection of a potentiation effect. Taken together,
these results suggest that p23/Tmp21 depletion in LNCaP cells enhances PKCδ
activation upon PMA stimulation.
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Figure 3.5 Depletion of PKCδ or PKC inhibition with GF 109203X blocks PMA-induced
apoptosis in LNCaP prostate cancer cells. A. Western blots for the expression of PKCδ and
p23/Tmp21 in LNCaP cells. B. LNCaP cells were transiently transfected with either control,
PKCδ, or PKCδ RNAi duplexes combined with a p23/Tmp21 RNAi duplex. Forty-eight h
later, cells were treated with 30 nM PMA for 1 h and apoptosis was assessed 24 h following
PMA treatment. C. Effect of the PKC inhibitor GF 109203 X (5 μM). GF 109203X (5 μM)
was added 1 h before PMA treatment. LNCaP cells expressing p23/Tmp21 shRNA were
treated with 30 nM PMA for 1 h and apoptosis was assessed 24 h later.
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Figure 3.6 Depletion of p23/Tmp21 accelerates PMA-induced GFP-PKCδ plasma
membrane translocation. A. Expression of p23/Tmp21 in LNCaP cells stably
expressing different p23/Tmp21 shRNAs (shRNA#1 and shRNA#2) or control
shRNA cells. B. pEGFP-PKCδ was transfected into different LNCaP cell lines using
the Amaxa Nucleofector. Forty-eight h later, cells were treated with PMA (30 nM).
Time-lapse images of GFP-PKCδ translocation in living cells were captured at
different times after PMA treatment. Peripheral translocation is marked with arrows.
Similar results were observed in two additional experiments.
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Figure 3.7 Depletion of p23/Tmp21 significantly enhances ROCK and JNK activation
by PMA. LNCaP cells with stable p23/Tmp21 depletion or control cells were treated
with PMA (30 nM) or vehicle for 10 min. MYPT1-Thr850 and phospho-JNK were
determined by Western blot. Two additional experiments gave the same results.
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DISCUSSION
In this chapter we report that p23/Tmp21, an ER/Golgi protein, negatively
regulates apoptosis of LNCaP prostate cancer cells in response to stimuli. p23/Tmp21
associates with PKCδ, and RNAi depletion of p23/Tmp21 results in enhanced
apoptotic death of LNCaP cells upon PMA or doxorubicin treatment. The interaction
is mediated by the PKCδ C1a-b domain. Moreover, we demonstrated that upon PMA
treatment, depletion of p23/Tmp21 enhances activation of PKCδ, as suggested by the
enhanced PKCδ plasma membrane translocation and the activation of PKCδ
downstream effctors ROCK and JNK. We conclude that p23/Tmp21 serves as a
perinuclear anchoring protein for PKCδ that limits PKCδ activation.
Recently, the involvement of p24 family proteins in apoptotic cell death was
reported. Brefeldin A, which causes ER stress by inhibiting protein transport into the
Golgi, significantly induces ERS25 gene expression. ERS25 is a novel identified
oxidative stress-responsive protein. Remarkably, shRNA-directed inhibition of
ERS25 attenuates oxidative stress-induced ROS and abrogates apoptotic cell death in
yeast upon H2O2 treatment (81). Thus, the p24 family proteins may contribute to
apoptotic death induced by ER stress. However, it is still elusive what is the exact
role of individual members of the p24 family in apoptotic cell death in response to
different stimuli.
Our previous studies in COS and HeLa cells, together with our yeast two-hybrid
analysis, demonstrated that p23/Tmp21 interacts with C1 domains in α-, β-chimaerin,
and PKCε (182). Our results support a model in which p23/Tmp21 serves as an
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anchoring protein receptor for C1 domain-containing proteins, that sequesters them in
the ER/Golgi region and prevents their translocation and activation. Likewise, our
present results demonstrate that depletion of p23/Tmp21 enhances PKCδ plasma
membrane translocation upon PMA treatment, suggesting a role for p23/Tmp21 as a
negative regulator of PKCδ translocation to the cell membrane or possibly other
compartments.
In many cell types, it has been demonstrated that PKCδ mediates apoptotic
responses initiated by a variety of stimuli, including chemotherapy agents, H2O2, viral
infection, phorbol esters, UV radiation, Fas-ligand, and ionizing radiation. In our
laboratory, we have established that PKCδ plays a critical role in mediating apoptosis
in androgen-sensitive prostate cancer cells. Using adenoviral overexpression of
PKCδ, it was revealed that PKCδ significantly enhances PMA-induced apoptosis of
LNCaP cells, whereas kinase-deficient PKCδ can substantially block PMA-induced
apoptosis of LNCaP cells, arguing that PKCδ is critical in regulation of apoptosis of
LNCaP cells (58). Recently, we identified a novel autocrine pro-apoptotic loop
triggered by PKCδ activation in prostate cancer cells. Blocking antibodies against
TNFα and TRAIL significantly inhibited apoptotic effects mediated by conditioned
medium collected from PMA-treated cells, suggesting that the release of death
receptor ligands by activation of PKCδ plays a important role in PMA-induced
apoptosis of androgen-dependent prostate cancer cells (66). Blocking TNF receptor 1
signaling significantly inhibited ER stress-induced cell death (105). ER stress signals
induced by docetaxel are mediated by JNK activation downstream of PKCδ
activation, as revealed by the fact that PKCδ RNAi significantly inhibit ER stress
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signaling. Interestingly, our previous experiments demonstrated that PKCδ-mediated
apoptosis in LNCaP prostate cancer cells is dependent on the JNK pathway (66, 193).
One speculation is that the ER stress signaling pathway possibly mediates PMAinduced apoptosis of LNCaP cells, and that p23/Tmp21 might be involved in ER
stress. Indeed, as mentioned above, one of p24 family member proteins, ERS25,
contributes to apoptotic cell death in yeast upon ER stress stimulus (81).
In summary, here we provide the first evidence that PKCδ-mediated apoptosis in
LNCaP cells can be negatively regulated by the ER/Golgi protein p23/Tmp21 through
their direct association. In addition, enhanced translocation of PKCδ to the plasma
membrane and activation of downstream effectors such as ROCK and JNK, were
observed in p23/Tmp21-depleted cells. This suggests a role for p23/Tmp21 in
anchoring PKCδ in the perinuclear compartment, which possibly impedes PKCδ
activation and translocation to the plasma membrane.
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MATERIAL AND METHODS
Cell Culture- LNCaP human prostate cancer cells were cultured in RPMI 1640
medium (ATCC) supplemented with 10% fetal bovine serum and penicillin (100
units/ml)-streptomycin (100 μg/ml). HeLa and COS-1 cells were cultured in
Dulbecco’s modified Eagles’s medium (Invitrogen) supplemented with 10% fetal
bovine serum and penicillin (100 units/ml)-streptomycin (100 μg/ml). All cells were
cultured at 37 °C in a humidified 5% CO2 atmosphere.

Generation of p23/Tmp21- depleted cell lines using shRNA lentivirus - LNCaP cells
were infected with 2 different MISSION® Lentiviral Transduction particles encoding
p23/Tmp21 shRNAs following the manufacture’s instructions. p23/Tmp21 shRNA
target sequences were as follows:
#1,CCGGCCAACTCGTGATCCTAGACATCTCGAGATGTCTAGGATCACGAG
TTGGTTTTT.
#2,CCGGCGCTTCTTCAAGGCCAAGAAACTCGAGTTTCTTGGCCTTGAAGA
AGCGTTTTT. Stable cell lines (pools) were generated by selection with puromycin
(1 μg/ml).

Yeast two-hybrid assays- Yeast two-hybrid assays were carried out essentially as
described in Chapter 2.

Western Blot analysis- Western blot was carried out essentially as described in
Chapter 2. The following primary antibodies were used: anti-PKCδ (Transduction
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Laboratories, Lexington, KY); anti-actin (Sigma); anti-phospho-JNK and anti-JNK
(Cell Signaling Technology, Beverly, MA); anti-p23/Tmp21 (Santa Cruz
Biotechnology, Inc., Santa Cruz, CA); and anti-phospho-MYPT1 (myosin
phosphatase target subunit 1)-Thr850 (Millipore, Billerica, MA). All antibodies were
used at a 1:1000 dilution except for the anti-actin antibody, which was used at a
1:20,000 dilution.

Apoptosis assays- The incidence of apoptosis was determined as we previously
described (58). Briefly, Cells were trypsinized, mounted on glass slides, fixed in 70%
ethanol, and then stained for 20 min with 1 mg/ml 4′,6-diamidino-2-phenylindole
(Sigma). Apoptosis was characterized by chromatin condensation and fragmentation
when examined by fluorescence microscopy. The incidence of apoptosis in each
preparation was analyzed by counting ~500 cells.

RNA interference- 21-bp double-stranded RNAs were purchased from Dharmacon
Research, Inc. (Dallas, TX) or Ambion (Austin, TX), and transfected into LNCaP
cells using the Amaxa Nucleofector (Amaxa Biosystems, Gaithersburg, MD)
following the instructions provided by the manufacturer. Experiments were
performed 48 h after transfection. The following targeting sequences were used:
CCATGAGTTTATCGCCACCTT

(PKCδ1),

CCATGTATCCTGAGTGGAA

(PKCδ2), GCCAUAUUCUCUACUCCAAUU (p23/Tmp21) (35). As a control we
used the Silencer® negative control 7 siRNAi (Ambion).
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Immunostaining and confocal microscopy- Immunostaining and confocal microscopy
were carried out essentially as described in Chapter 2.
Time-lapse microscopy- LNCaP cells were transfected with pEGFP-PKCδ using the
Amaxa Nucleofector and seeded into glass-bottomed culture dishes (MatTek,
Ashland, MA) for 48 h. Cells were cultured for 20 h in Phenol red-free RPMI-1640
medium containing 10% FBS and 5 mM HEPES. Cells were monitored under a
fluorescence microscope (Nikon Eclipse TE2000U) at a 488 nm excitation
wavelength with a 515 nm-long pass barrier filter at 25°C.
Co-immunoprecipitation- LNCaP cells were washed once with PBS, and then lysed
for 10 min at 4°C in 800 μl of a lysis buffer containing 20 mM Tris-HCl, pH 7.5, 100
mM NaCl, 0.5 mM EDTA, 0.5 mM EGTA, 0.5% TritonX 100, 1 mM betaglycerophosphate and a protease inhibitor cocktail (Sigma). Cell lysates were
centrifuged at 14, 000 × g and the supernatant was precleared with 15 μl of protein A
agarose beads (Invitrogen) for 1 h at 4°C. After a short centrifugation, the supernatant
was used for immunoprecipitation with an anti-PKCδ antibody or control IgG (4 °C,
2 h). Protein A beads (20 μl) were then added and the mixture was incubated at 4°C
for 2 h. The beads were extensively washed in lysis buffer and boiled. Samples were
resolved in a 12% SDS-polyacrylamide gel and transferred to a polyvinylidene
difluoride membrane (Millipore Co., Bedford, MA) for Western blot analysis.
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CHAPTER 4
C1 domain-mediated translocation of PKCε: implications for
prostate cancer radioresistance
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ABSTRACT
The molecular mechanisms for radioresistance of cancer cells are not completely
understood. Epidermal growth factor receptor (EGFR) activation by ionizing
radiation has been documented as one of the major mechanisms of cytoprotection. As
EGFR couples to PLCγ and DAG generation, we decided to investigate whether C1
domain-containing proteins modulate radiosensitivity. The role of individual PKC
isozymes in prostate cancer radiosensitivity still remains elusive. Here, we provide
evidence that PKC isozymes play distinct roles in PC3 prostate cancer cell
radiosensitivity. The PKC inhibitor GF 109203X radiosensitizes PC3 cells in a dosedependent manner. Using a lentiviral approach to silence PKCα, PKCδ or PKCε, we
demonstrated that only PKCε confers radioresistance to PC3 cells. Interestingly, a
clinically relevant dose of γ-irradiation (2 Gy) significantly enhanced PKCε
translocation from the cytosol to a particulate fraction. Confocal microscopy studies
demonstrated that upon γ-irradiation, the EGFR inhibitor AG1478 as well as
PLC inhibitor U73122 significantly impair PKCε translocation to the plasma
membrane. Furthermore, the reactive oxygen species (ROS) scavenger N-acetylcysteine (NAC) also blocked PKCε translocation to the plasma membrane. Our study
revealed a potential role for DAG and C1 domain-containing proteins in the control
of ionizing irradiation-induced cell death/survival.
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INTRODUCTION
Ionizing radiation is widely used to treat different types of solid tumors. However,
radioresistance occurs in many cases and is likely to be the underlying mechanism of
selection and repopulation in tumors. DNA damage/repair and cell cycle checkpoint
pathways are key regulatory mechanisms that determine the fate of cancer cells after
irradiation (72, 96, 110). In addition, many studies revealed that cell membranerelated signaling events are also involved in survival/death responses. Studies by
many laboratories demonstrated that ionizing radiation activates receptor tyrosine
kinases (RTK), mitogen-activated protein kinases (MAPKs), and PKCs (41, 76, 77,
90, 154, 167, 176, 177, 187). EGFR, a member of ErbB family of RTKs, could be
activated by clinically relevant doses of ionizing radiation (1-5 Gy), confirming that
ionizing radiation can mimic EGF effects and lead to the activation of cytoprotective
signaling pathways, primarily the MAPK cascades (2, 168). Ionizing radiation also
stimulates sphingomyelin-to-ceramide conversion via sphingomyelinases. Ceramide
is a sphingolipid-derived second messenger capable of initiating apoptotic cascades in
response to various stressful stimuli (38, 73, 116). Interestingly, DAG is also
generated from cell membranes by ionizing radiation (129). Moreover, DAG analogs
such as the phorbol esters can block ceramide-dependent apoptosis by various stimuli,
including H2O2 (63), TNFα (47, 139), chemotherapy agents (67), and ionizing
radiation (73, 120, 131, 175), arguing that DAG-dependent signaling pathways may
play an anti-apoptotic role in some contexts.
Extensive studies have established the relative contribution of individual PKC
isozymes to cancer initiation, cell cycle progression, transformation, apoptosis, and
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senescence (70). However, the role of individual PKCs in radiation-induced cancer
cell death remains unknown. As radiotherapy is widely used to treat prostate cancer,
we chose PC3 androgen-independent prostate cancer cells as a model to explore the
relevance of individual PKCs in radiation-induced cancer cell death. Most prostate
cancer cells express three DAG/phorbol ester responsive PKCs: PKCα, PKCδ and
PKCε (58). Based on the established roles of PKC isozymes in controlling cell fate in
response to stimuli and their ability to regulate apoptotic and survival pathways, we
hypothesize that PKC isozymes can modulate the sensitivity of cells to radiation. One
attractive scenario is that PKCε, which is widely implicated in the control of survival
signals to promote resistance to radiation-induced death. The results of our analysis
revealed that PKC isozymes played differential roles in irradiation-mediated PC3 cell
death. Depletion of PKCε significantly radiosensitizes PC3 cells, suggesting that
PKCε confers cytoprotection to PC3 prostate cancer cells in response to γ-irradiation.
Moreover, we established a key role for DAG, the C1 domain ligand, in plasma
membrane translocation of PKCε by γ-irradiaiton.
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RESULTS
γ-irradiation inhibits the growth of PC3 androgen-independent prostate
cancer cells
In clinic, radiotherapy has been widely used to treat prostate cancer. PC3
androgen-independent prostate cancer cells (5 x 104/well) were seeded (DMEM with
10% FBS) in six-well plates. As shown in Figure 4.1A, the cell number was counted
at 24, 48, 72, and 96 h after the culture. The number of PC3 cells increased about 60fold after 96 h. As shown in Figure 4.1C and Figure 4.1D, PC3 cell number was
significantly reduced upon γ irradiation in a dose-dependent manner. Apoptosis
analysis by DAPI staining revealed that γ-irradiation (8 Gy) causes only about 10%
apoptosis (Figure 4.1B), suggesting that γ-irradiation-mediated inhibition of PC3 cell
growth involves primarily other mechanisms.

The PKC inhibitor GF 109203X (GF) radiosensitizes PC3 prostate cancer cells
To examine a potential involvment of PKC isozymes on γ-irradiation-mediated
prostate cancer cell death in vitro, PC3 cells were pre-treated with the pan-PKC
isozyme inhibitor GF for 30 min and then subject to a clonogenic survival assay. As
shown in Figure 4.2A, the PKC inhibitor significantly radiosensitizes PC3 prostate
cancer cells. γ-irradiation (8 Gy) alone causes about 8% apoptosis. GF enhanced γirradiation-induced apoptosis to 13% and 20% at the concentration of 1 μM and 5
μM, respectively. Our results suggest that inhibition of PKC isozymes by GF
radiosensitizes PC3 androgen-independent prostate cancer cells.
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Figure 4.1 γ-irradiation reduces PC3 prostate cancer cell number. PC3 prostate
cancer cells (5x104/well) were seeded into six-well plates and irradiated by different
dose of γ-irradiation. Cell number was determined at 24, 48, 72 and 96 h after
irradiation. A. PC3 prostate cancer cell growth curve. Cell number was determined at
24, 48, 72, and 96 h. B. Apoptosis was analyzed by DAPI staining 72 h after γirradiation (2, 4, 6, and 8 Gy). The results are from 3 separate experiments (mean ±
SE). C. PC3 cells were trypsinized and cell number was determined 72 h after
different γ-irradiation doses. D. Representative images of PC3 cell density 72 h after
γ-irradiation.
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Figure 4.2 The PKC inhibitor 109203X (GF) radiosensitizes PC3 prostate cancer
cell. A. PC3 cells were serum-starved for 72 h, treated with different concentrations
of the PKC inhibitor GF for 30 min and subject to γ-irradiation. After irradiation,
cells were seeded into 60 mm Petri dishes and colonies in each plate counted after 15
days. The survival fraction was calculated as: colonies /[cells seeded x (plating
efficiency)/100]. Each sample was done in triplicate. Two additional experiments
showed similar results. B. Apoptosis was measured by DAPI staining 72 h after γirradiation (8 Gy). The results are from 3 separate experiments (mean ± SE).
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Establishment of PC3 prostate cancer cell lines stably depleted of PKCα, PKCε
and PKCδ
In order to determine the role of individual DAG-responsive PKC isoforms in PC3
cell radiosensitivity, we used shRNA lentiviruses to specifically knockdown PKCα,
PKCδ, or PKCε , the main PKC isozymes expressed in prostate cancer cells. As a
control, we used a non-target sequence shRNA lentivirus. Stable cell lines (pools)
were selected using puromycin. As shown in Figure 4.3, PC3 prostate cancer cell
lines with >50% depletion of PKCα, PKCδ, or PKCε could be successfully
established using this approach. We picked two cell lines for each PKC that show
isozyme-specific depletion (#2 and #3 for PKCα; #2 and #4 for PKCδ; #1 and #4 for
PKCε).

PKCε depletion significantly radiosensitizes PC3 prostate cancer cells
In the next series of experiments, we assessed the effect of specific PKC isozyme
depletion on PC3 cell radiosensitivity. Clonogenic survival assays revealed that
depletion of PKCδ has no sensitizing effect on γ-irradiation (Figure 4.4A). Likewise,
PKCα depletion has no significant effects on clonogenic survival (Figure 4.4B). It
has been reported that PKCε confers androgen independence, accelerates G1/S
transition, and enhances tumorigenic potential in nude mice when overexpressed in
LNCaP cells. PKCε also activates the mitogenic ERK pathway, and propagates
survival signals in the absence of functional PTEN (190-192). Notably, human
prostate tumors display very high levels of PKCε (5, 44, 94, 121).
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Figure 4.3 Establishment of PC3 prostate cancer cell lines stably depleted of PKCα,
PKCε or PKCδ by using shRNA lentiviral expression system (MISSION® lentiviral
particles, Sigma). PKCα (#2, #3), PKCε (#1, #4) and PKCδ (#2, #4) PC3 cell lines
were chosen for subsequent experiments.
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Figure 4.4 PKCα or PKCδ depletion does not affect PC3 cell radiosensitivity. A.
Survival curve for PKCα-depleted PC3 cell lines. B. Survival curve for PKCδdepleted PC3 cell lines. Western blots showing the depletion of either PKC isozyme
are shown. Two additional experiments show similar results.
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In addition, de-regulation of the PKCε gene has been reported in other cancer types,
such as in lung, breast and thyroid cancer (6, 92, 115). Whether PKCε is implicated in
prostate cancer cell survival in response to γ-irradiation is not known. We irradiated
the PKCε-depleted cell lines and examined their survival. We found that depletion of
PKCε significantly radiosensitizes PC3 prostate cancer cells, suggesting that PKCε
plays a pro-survival role in response to γ-irradiation (Figure 4.5).

γ-irradiation promotes PKCε translocation to the plasma membrane
Early studies by Nakajima et al. reported that ionizing radiation can generate DAG
and translocate PKCs to plasma membrane in rat hepatocytes (129, 130). We decided
to investigate whether PKCε can be redistributed to membranes in response to γirradiation in PC3 cells. Using a subcellular fractionation approach we found that γirradiation (2 Gy) could induce translocation of PKCε from cytosol to the particulate
fraction (Figure 4.6A). As a second approach we expressed GFP-PKCε in PC3 cells
and assessed its localization in response to γ-irradiation. Confocal images revealed
that GFP-PKCε significantly translocates to the plasma membrane 5 min after γirradiation (2, 4, 6 Gy) (Figure 4.6B). As PKCs become activated when translocated
to the plasma membrane, these results strongly suggest that γ- irradiation activates
PKCε.
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Figure 4.5 PKCε depletion enhances radiosnsitivity of PC3 cells. Left panel, survival
curve for PKCε-depleted cell lines. Right panel, Western blot showing depletion of
PKCε in PC3 prostate cancer cells.
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Figure 4.6 Translocation of PKCε after γ-irradiation. A. Subcellular fractionation of
PKCε after γ-irradiation. After serum starvation for 72 h, PC3 cells were subjected to
γ-irradiation. After 2 h, cell lysates were fractionated into cytosolic and particulate
fractions by centrifugation. PKCε levels were determined by Western blot using a
specific anti-PKCε antibody. Similar results were obtained in two experiments. B.
PC3 prostate cancer cells were transfected with pEGFP-PKCε, serum-starved for 72
h, and then irradiated with different doses of γ-irradiation. Cells were fixed in cold
ethanol (-20oC) 5 min after irradiation and images were captured by fluorescence
microscopy. Representative pictures are shown. Two additional experiments gave
similar results.

115

Reactive oxygen species (ROS) mediate PKCε translocation by γ-irradiation
The active hydroxyl radical (OH-) is the primary species of ROS produced by
ionizing radiation (150). It can produce other highly reactive species, such as
superoxide (O2.-) and hydrogen peroxide (H2O2). Hydrogen peroxide (H2O2) has
been reported to stimulate DAG production in vascular endothelial cells (170).
UV radiation also has been reported to generate DAG in human melanocytes and
keratinocytes (31). We hypothesize that subcellular translocation of PKCε in PC3
cells by γ-irradiation is mediated by ROS. To address this issue we used the ROS
scavenger N-acetyl-L-cysteine (NAC). As shown in Figure 4.7, γ-irradiation alone
induced PKCε translocation to the cell periphery (middle panel). In contrast,
pretreatment of NAC (5 mM) abolished plasma membrane translocation of PKCε
(low panel), arguing that ionizing radiation-induced ROS are implicated in PKCε
plasma membrane relocalization. Interestingly, perinuclear localization of PKCε
remained unaffected in the presence of NAC.

The EGFR inhibitor AG1478 impairs peripheral PKCε translocation by γirradiation
It has been reported that EGFR is activated by ionizing radiation in human
cancer cells, and that it mediates cytoprotective responses and radioresistance.
Amorino et al. reported that ionizing radiation (1-5 Gy) activates EGFR and ERK
in human breast carcinoma cells. ERK and its downstream effector p90Rsk could
phosphorylate downstream transcription factors involved in cell proliferation,
such as CREB, Egr, Est, Stat3, C/EBP and Stat1 (2).
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Figure 4.7 NAC prevents γ-irradiation-mediated PKCε translocation. PC3 prostate
cancer cells expressing GFP-PKCε were serum-starved for 72 h and then treated with Nacetyl-L-cysteine (NAC, 5 mM) for 1 h. Cells were then subjected to γ-irradiation (4 Gy)
for 5 min and then fixed in cold ethanol (-20oC). Images were captured by confocal
microscopy. Two additional experiments showed similar results.
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It has been reported that γ-irradiation promotes EGFR phosphorylation at
Tyr992 even at higher levels than those induced by EGF. Tyr992 in EGFR
couples to PLCγ and DAG generation (167), arguing that irradiation-induced
EGFR activation may activate PKCs via DAG binding to their C1 domains. We
therefore tested the hypothesis that PKCε translocation to the plasma membrane
by irradiation is mediated by the EGFR-PLCγ pathway. PC3 prostate cancer cells
were transfected with pEGFP-PKCε, serum-starved for 72 h, treated with the
EGFR inhibitor AG1478 (10 μM, 1 h), and then γ-irradiated (4 Gy, 5 min). Cells
were fixed and the images were captured by confocal microscopy. As shown in
Figure 4.8A, AG1478 impaired the peripheral translocation of PKCε. To
determine a potential involvment of PLC in PKCε translocation, we used the PLC
inhibitor U73122. Its inactive analogue U73433 was used as a negative control.
As shown in Figure 4.8B, the PLCγ inhibitor impaired γ-irradiation-induced
PKCε membrane translocation. Neither vehicle nor U73433 impaired the
peripheral relocalization of GFP-PKCε. Altogether, these results suggest that
PKCε plasma membrane translocation by γ-irradiation is mediated through the
activation of the EGFR-PLCγ-DAG signaling pathway. Binding of DAG to the
C1 domain in PKCε may represent the key event in the translocation of this
kinase and its consequent activation.
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A

B

Figure 4.8 PKCε translocation to the plasma membrane by γ-irradiaiton is
mediated by EGFR and PLC. PC3 prostate cancer cells expressing GFPPKCε were serum-starved for 72 h and then treated with: A. AG1478, or B.
U73122 or its inactive analogue U73433. Cells were then irradiated (4 Gy, 5 min),
and fixed in cold ethanol (-20oC). Images were captured by confocal microscopy.
Two additional experiments showed similar results.
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DISCUSSION
Prostate cancer is the most commonly diagnosed male non-skin cancer
malignancy and second only to lung cancer in human male cancer-related
mortality. Although radiotherapy has been widely used in prostate cancer
treatment, locally-advanced stages of prostate cancer (LAPC) will relapse after
treatment. The underlying mechanisms for LAPC radioresistance are not fully
understood. One of the clinical goals in radiotherapy is to achieve the eradication
of cancer cells through the combination of radiotherapy and other radiosensitizing
regimes. PKC isozymes are implicated in the regulation of cell proliferation,
transformation, differentiation, apoptosis, and the metastatic cascade (70). Some
studies demonstrated that PKC isozymes are involved in stress-mediated cell
death. Oxidative stress such as H2O2 treatment increases intracellular ceramide
and decreases DAG levels (63). PKCδ has been reported to be involved in
apoptosis after irradiation of U937, MCF7, and NIH 3T3 cells (54, 59, 97, 200).
More recently, PKCε was reported to sensitize skin to UV radiation (5). However,
the relevance of individual PKC isozymes in prostate cancer cell radiosensitivity
remains elusive. The purpose of this study was to assess the function of individual
PKC isozymes in γ-irradiation-mediated prostate cancer cell death. We
demonstrated that inhibition of PKC activity by GF109203X radiosensitizes PC3
prostate cancer cells and significantly enhances γ-irradiation-mediated apoptosis.
However, the fact that PKC isozymes exert different cellular functions required an
analysis using specific inhibition or depletion of each PKC isozyme. As
pharmacological inhibitors of PKC isozymes may not be very specific, we
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decided to use shRNA lentiviruses to stably deplete PKCα, PKCδ or PKCε from
PC3 cells. Clonogenic survival assays revealed that depletion of PKCε
significantly radiosensitizes PC3 prostate cancer cells. In contrast, neither PKCα
nor PKCδ depletion has any significant effect. These results revealed differential
roles for discrete PKC isozymes in radiosensitivity of PC3 prostate cancer cells.
Our analysis also supports the notion that membrane-activated signaling pathways
play important roles in the regulation of radiation-mediated cell death/survival.
Irradiation could induce PKC activation, and several studies suggested
potential roles for PKC in radiosensitization (73, 76, 77, 90, 129, 130, 164). γirradiation induces DAG production and activates PKC in cultured rat hepatocytes
(129, 130). Our present study demonstrates that PKCε translocates from the
cytosol to the plasma membrane upon γ-irradiation. This effect is mediated by
EGFR, as determined with EGFR inhibitor AG1478. Ionizing radiation causes a
strong phosphorylation of Tyr992 in EGFR, a residue responsible for PLCγ
docking. Therefore, it may be possible that DAG generated in response to γirradiation via PLCγ binds to the C1 domain in PKCε, and that this represents the
key event that causes PKCε activation, ultimately resulting in radioresistance. Not
surprisingly, a PLC inhibitor impairs PKCε translocation by γ-irradiation.
There is extensive evidence that PKCε mediates survival responses. Studies in
the myocardium demonstrated a cardio-protective and anti-apoptotic role for
PKCε in ischemic preconditioning (37, 68, 106, 146). Association of an active
PKCε mutant with Src and Lck has been demonstrated to activate each of these
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soluble tyrosine-kinases, and these interactions can be enhanced by ischemic
preconditioning (145, 180). PKCε associates with Akt, Bax and Bcl-2 in prostate
cancer cells to modulate cellular apoptosis (121, 192). When overexpressed in
LNCaP androgen-dependent prostate cancer cells, PKCε confers androgen
independence, accelerates G1/S transition, and enhances tumorigenic potential of
these cells when inoculated into nude mice (190). More recently, Akt has been
shown to be an effector of PKCε that is implicated in the protection from ionizing
radiation- and TNFα-induced breast cancer cell death (108). In our laboratory we
generated a prostate-specific PKCε transgenic mice that show prostatic
hyperplasia and low-grade PINs (prostate intraepithelial neoplasia). These lesions
present elevated levels of phospho-Akt, phospho-S6 and phospho-mTOR,
suggesting enhanced survival signaling driven by PKCε (unpublished data). As
PKCε is overexpressed in human prostate cancer, our results suggest that this
kinase may represent an important mediator of prostate cancer progression. We
speculate that PKCε-specific inhibitors may be useful not only for the
therapeutics of prostate cancer but also for sensitizing prostate cancer cells to
chemotherapy and radiotherapy. From a mechanistic standpoint, our results
support the concept that DAG-induced activation of PKCε is an essential step in
radioresistance. Translocation of PKCε to the plasma membrane via PLCγ-DAG
is required for the pro-survival effect. On the other hand, PKCε located in the
perinuclear region (possibly bound to p23/Tmp21) is dispensable for survival.
Thus, C1 domain-mediated translocation of PKCε to the plasma membrane is a
key

event

in
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radioresistance.

MATERIALS AND METHODS
Materials, cell culture and transfections-Described in Chapter 2.

Generation of PKCα, PKCδ and PKCε-depleted cell lines using shRNA
lentiviruses- PC3 cells were infected with MISSION® lentiviral transduction
particles encoding PKCα, PKCδ, or PKCε shRNAs. PKCα, PKCδ, or PKCε
shRNA target sequences are shown in Table 4.1. Stable cell lines (pools) were
generated by selection with puromycin (1 μg/ml).

Apoptosis assays- Determination of apoptosis was carried out essentially as
described in Chapter 2.

Irradiation protocol- PC3 cells were serum-starved for 72 h and then irradiated at
different doses once using a Nordian GammaCell 40 irradiator.

Clonogenic assay- PC3 cells were trypsinized under sterile condition and plated
into 60 mm tissue culture Petri dishes in triplicates at 100 cells/well (0, 2 Gy); 400
cells/well (4 Gy); 1,000 cells/well (6 Gy) and 2,000 cells/well (8 Gy). After 2
weeks, cells were fixed and stained with methylene blue. The number of colonies
consisting of 50 or more cells was scored.

Fluorescence microscopy- pEGFP-PKCε was transfected into PC3 cells using
Lipofectamine 2000. After 24 h, cells were serum-starved for 72 h, subjected to γ-
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irradiation for 5 min and fixed with cold ethanol (-20 oC) for 10 min. Slides were
mounted using Fluoromount-G (SouthernBiotech, Birmingham, AL) and viewed
with a Carl Zeiss LSM 710 laser-scanning microscope. The confocal images were
processed with LSM Image Browser. Images represent individual middle sections
of projected Z-series mounting.

Western blot- Experiments were carried out essentially as described in Chapter 2.

Subcellular fractionation- PC3 cells were harvested 2 h after γ-irradiation into
lysis buffer (50 mM Tris-HCl, pH 7.4, 5 mM EGTA, 5 μg/ml 4-(2-aminoethyl)benzenesulfonyl fluoride, 5 μg/ml leupeptin, 5 μg/ml aprotinin, and 1 μg/ml
pepstatin A) and lysed by sonication. Separation of cytosolic (soluble) and
particulate fractions was performed by ultracentrifugation as described previously
(181). Equal amounts of protein (10 μg) for each fraction were subjected to SDSpolyacrylamide gel electrophoresis, transferred to PVDF membranes, and
immunostained with an anti-PKCε antibody.
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Table 4.1 Sequences of MISSION® shRNA lentiviral transduction particles used
to generate PKCα, PKCδ, or PKCε stably-depleted PC3 cell lines.
______________________________________________________________________
PKCα shRNA:
TRCN0000001690 (PKCα #1)
CCGGCTTTGGAGTTTCGGAGCTGATCTCGAGATCAGCTCCGAAACTCCAAAGTTTTT
TRCN0000001691 (PKCα #2)
CCGGCGAGCTATTTCAGTCTATCATCTCGAGATGATAGACTGAAATAGCTCGTTTTT
TRCN0000001692 (PKCα #3)
CCGGCATGGAACTCAGGCAGAAATTCTCGAGAATTTCTGCCTGAGTTCCATGTTTTT
TRCN0000001693 (PKCα #4)
CCGGCCCGTCTTAACACCACCTGATCTCGAGATCAGGTGGTGTTAAGACGGGTTTTT
TRCN0000001694 (PKCα #5)
CCGGACGGCTTGTGTCTGATTCCATCTCGAGATGGAATCAGACACAAGCCGTTTTTT

PKCε shRNA:
TRCN0000000844 (PKCε #1)
CCGGGCAGAACTCAAGGGCAAAGATCTCGAGATCTTTGCCCTTGAGTTCTGCTTTTT
TRCN0000000845 (PKCε #2)
CCGGCCCTTCAAACCACGCATTAAACTCGAGTTTAATGCGTGGTTTGAAGGGTTTTT
TRCN0000000846 (PKCε #3)
CCGGCCACAAGTTCGGTATCCACAACTCGAGTTGTGGATACCGAACTTGTGGTTTTT
TRCN0000000848 (PKCε #4)
CCGGGCCAGAAGGAAGAGTGTATGTCTCGAGACATACACTCTTCCTTCTGGCTTTTT

PKCδ shRNA:
TRCN0000010193 (PKCδ #1)
CCGGGGCCGCTTTGAACTCTACCGTCTCGAGACGGTAGAGTTCAAAGCGGCCTTTTT
TRCN0000010194 (PKCδ #2)
CCGGCAAGGCTACAAATGCAGGCAACTCGAGTTGCCTGCATTTGTAGCCTTGTTTTT
TRCN0000010202 (PKCδ #3)
CCGGGCAAGACAACAGTGGGACCTACTCGAGTAGGTCCCACTGTTGTCTTGCTTTTT
TRCN0000010203 (PKCδ #4)
CCGGGCAGGGATTAAAGTGTGAAGACTCGAGTCTTCACACTTTAATCCCTGCTTTTT

__________________________________________________________________
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CHAPTER 5

Final Remarks
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The second messenger DAG signaling pathway has gained great attention as a
crucial regulatory mechanism in the control of cell proliferation, differentiation,
apoptosis, cancer initiation and progression. Cysteine-rich (C1) domains were
first identified in PKC isozymes as the motifs that bind DAG and phorbol esters.
Now it is recognized that C1 domains are also present in chimaerins, RasGRPs,
MRCKs, PKDs, DGKs, and Munc-13s (21, 86). Upon binding DAG or phorbol
esters, C1 domain-containing proteins translocate to the plasma membrane and
other intracellular compartments, including the nuclear membrane, the perinuclear
region, the nucleus, and mitochondria. Remarkably, redistribution of C1 domaincontaining proteins to distinctive compartments has a significant degree of
isozyme-selectivity and ligand-dependence. In addition to their plasma membrane
targeting, specificity of PKC isozymes function is also controlled by their
association with interacting proteins. In this thesis research, I have studied the
regulations and functions of proteins regulated via their C1 domains, including
β2-chimaerin, PKCδ and PKCε, in different paradigms in which protein-protein
interactions and C1 domain targeting are involved.
In Chapter 2 of this thesis, I present evidence that p23/Tmp21 acts as a C1
domain-docking protein that mediates perinuclear translocation of β2-chimaerin.
Glu227 and Leu248 in the β2-chimaerin C1 domain are crucial for binding
p23/Tmp21 and perinuclear targeting. β2-chimaerin (Glu227/Leu248) mutant is
more active as a Rac-GAP than wild-type β2-chimaerin. Our previous finding that
overexpression of p23/Tmp21 significantly inhibits β2-chimaerin Rac-GAP
activity in COS cells (180), suggests that association of β2-chimaerin with
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p23/Tmp21 limits activation. Recently, a unique phosphorylation site, Ser169, on
the β2-chimaerin Rac-GAP was identified. Phosphorylation at this site by another
DAG/phorbol esters receptor (PKCδ) negatively regulates β2-chimaerin plasma
membrane translocation, association with V12Rac1, and Rac-GAP activity
(Griner et al., submitted for publication). Thus, both Ser169 phosphorylation by
PKCδ and association with p23/Tmp21 represent mechanisms that modulate RacGAP activity of β2-chimaerin (Figure 1.9), suggesting a crosstalk between DAG
receptors. Importantly we also found that PKCδ interacts with p23/Tmp21 in the
perinuclear region (Chapters 2 and 3). Furthermore, unpublished data revealed
that PMA-induced phosphorylation of β2-chimaerin is significantly decreased in
HeLa cells in which p23/Tmp21 has been depleted using shRNA. Collectively,
these results imply that p23/Tmp21 plays a role in regulating PKCδ-mediated β2chimaerin phosphorylation. One speculation is that p23/Tmp21 may act as a
scaffold protein or a platform for PKCδ-mediated phosphorylation of β2chimaerin. Another possibility might be that phosphorylated β2-chimaerin
preferentially associates with p23/Tmp21 in the perinuclear ER/Golgi region.
Future experiments are needed to dissect the role of p23/Tmp21 in the
phosphorylation of β2-chimaerin and determine if Ser169 phosphorylation of β2chimaerin affects its association with p23/Tmp21. It still remains unclear what is
the physiological function of the p23/Tmp21-β2-chimaerin interaction in
perinuclear/Golgi region upon stimulation by DAG/phorbol esters. We previously
demonstrated that p23/Tmp21 overexpression counteracts the β2-chimaerin RacGAP activity. Our present study revealed that disruption of p23/Tmp21-β2128

chimaerin complex enhances chimaerin Rac-GAP activity. Therefore, we propose
that p23/Tmp21 might act as an anchoring protein for β2-chimaerin. This may
serve various purposes. One is a potential involvement of this Rac-GAP in
maintaining a pool of inactive Rac in the perinucleus that can mobilize to the
plasma membrane in response to different stimuli (see below). Another possible
scenario could be that p23/Tmp21 participates in the intracellular trafficking and
sorting. We do not have any experimental results to support this hypothesis, and
therefore further studies are needed to dissect this possible process. Time-lapse
images demonstrated that upon EGF or PMA treatment, β2-chimaerin translocates
to plasma membrane within 5 min. and then relocalize to the perinuclear region.
We thought this dual translocation of β2-chimaerin might be involved in two
steps. In the first step, β2-chimaerin translocates to plasma membrane to interact
with Rac-GTP and down-regulate Rac signals. Subsequently, β2-chimaerin, after
an unknown modification (may be phosphorylation by PKCδ), might preferably
bind to p23/Tmp21 and translocate from plasma membrane to perinuclear region.
Rac is generally thought to cycle between a cytosolic inactive form and an active
plasma membrane form. Because a pool of β2-chimaerin localizes to the plasma
membrane upon activation, it is possible that this pool of β2-chimaerin
deactivates Rac at that location. Recent studies have shown that a large pool of
Rac is located in the perinuclear region and that this pool of Rac is in its GDPbound form (95). We speculate that β2-chimaerin might play a role in the
maintenance of this perinuclear pool of Rac in an inactive state before this RacGTPase moves to the plasma membrane. Another speculation is that β2-chimaerin
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might be very important for maintaining Golgi structure or functions. Indeed, a
previous study revealed that α1-chimaerin regulates Golgi stability during
interphase (Alonso, M., et al. Eur J Cell Biol 76:93-101.). Further studies are
needed to investigate the role of β2-chimaerin in Golgi functions.
Interestingly, isolated C1 domains from individual PKC isozymes or RasGRP1
differentially interact with p23/Tmp21. In Chapter 3 of this thesis, we
demonstrated using a yeast two-hybrid assay that the PKCδ C1a-b domain
interacts with p23/Tmp21. Co-localization analysis by confocal microscopy
demonstrated that the C1b domain in PKCδ is the motif that interacts with
p23/Tmp21 in the perinuclear region. In addition, immunoprecipitation analysis
and confocal images demonstrated that PKCδ and p23/Tmp21 form a complex in
LNCaP cells. Future experiments are needed to address whether PKCδ C1b
domain interacts with p23/Tmp21 in the same way as PKCε C1b and β2chimaerin C1 domains. Mutations in the corresponding amino acids in PKCδ
should abolish its association with p23/Tmp21 and promote its activity.
Our laboratory and others have established that androgen-dependent prostate
cancer cells undergo apoptosis upon phorbol ester treatment, and that the effect
was primarily mediated by PKCδ. By using this paradigm, I now demonstrated
that depletion of p23/Tmp21 significantly potentiates PMA-induced apoptosis in
LNCaP cells, and notably the effect was rescued by PKCδ RNAi depletion or
treatment with a PKC inhibitor, suggesting that the potentiating apoptotic effect of
p23/Tmp21 depletion was mediated by PKCδ. Interestingly, disruption of PKCδp23/Tmp21 association by depletion of p23/Tmp21 enhances PMA-induced
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PKCδ plasma membrane translocation and activation of the PKCδ downstream
effectors ROCK and JNK, indicating p23/Tmp21 acts as an anchoring protein that
limits PKCδ activation and negatively regulates PMA-induced apoptosis in
LNCaP cells. Furthermore, our experiments also demonstrated that depletion of
p23/Tmp21 potentiates doxorubicin-mediated apoptosis, a PKCδ-dependent effect
(143). Thus p23/Tmp21 is a negative modulator of PKCδ-mediated responses.
Based on the results presented here, it would be also important to determine if
p23/Tmp21 modulates response by RasGRP1 or PKCε. One speculation is that
depletion or down-regulation of p23/Tmp21 might lead to more availability of
RasGRP1 or PKCε. Since these two proteins play important roles in cell
transformation, p23/Tmp21 may be also implicated in cancer progression. It
would be interesting to analyze the p23/Tmp21 expression profile in different
cancer cell lines and tumor samples to determine any potential relationship
between p23/Tmp21 expression and tumor progression.
In Chapter 4 of this thesis, I demonstrated that PKC inhibition radiosensitizes
PC3 prostate cancer cells. Using a lentiviral-based shRNA delivery approach, I
demonstrated that depletion of PKCε but not PKCα or PKCδ radiosensitizes PC3
cell. In addition, our experiments revealed that clinically relevant doses of γirradiation significantly enhanced PKCε translocation from the cytosol to the
particulate fraction. Moreover, confocal images demonstrated that the EGFR
inhibitor AG1478, PLC inhibitor U73122, as well as the reactive oxygen species
(ROS) scavenger NAC significantly impair γ-irradiation-induced translocation of
PKCε to the plasma membrane, suggesting that PKCε is a downstream effector of
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the ROS-EGFR-PLCγ-DAG signaling pathway and may confer cytoprotective
effects upon ionizing radiation. It would be important to determine how activated
PKCε relays signals to downstream effectors that generate the cytoprotective
effects. PKCε can activate MAPKs and lead to the expression of transcription
factors, such as CREB, Egr, Est, Stat3, C/EBP and Stat1. PKCε may also activate
Akt or Bcl-2 family members to generate pro-survival effects. In any case, a
detailed analysis would be needed to investigate the mechanisms involved in
PKCε-mediated radioresistant effects. It will be also worthwhile to examine the
radiosensitizing effect of PKCε specific inhibitors. Conceivably, specific
inhibition of PKCε may be a useful therapeutic approach to sensitize prostate
cancer cells or other cancer cells to γ-irradiation. Not surprisingly, PKCε also
modulates the sensitivity of cancer cells to chemotherapeutic agents (10). Our
study highlights the relevance of membrane-related signal cascades other than
irradiation-induced DNA damage/repair pathways in controlling ionizing
irradiation-induced cell death.
In summary, our studies suggest that the C1 domain plays important roles in
modulating the activation of signaling molecules via dual mechanism (Figure
5.1). Both lipid binding and protein-protein interactions determine the localization
of C1 domain-containing proteins, and these represent essential steps in the
activation of these proteins.
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Figure 5.1 Proposed model of regulation of the C1 domain-containing proteins.
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